CINXE.COM

<!DOCTYPE html><html data-theme="light" class="light" lang="en" data-marquee="stopped"><head><meta charSet="utf-8" data-next-head=""/><meta name="viewport" content="width=device-width, initial-scale=1" data-next-head=""/><link rel="alternate" hrefLang="x-default" href="https://stocktwits.com/symbol/AVXL" data-next-head=""/><title data-next-head="">Anavex Life Sciences Corporation (AVXL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News</title><meta property="og:title" content="Anavex Life Sciences Corporation (AVXL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News" data-next-head=""/><meta name="twitter:title" content="Anavex Life Sciences Corporation (AVXL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News" data-next-head=""/><meta property="og:image:width" content="200" data-next-head=""/><meta property="og:image:height" content="200" data-next-head=""/><meta name="twitter:card" content="summary_large_image" data-next-head=""/><meta name="twitter:image" content="https://stocktwits.com/images/stocktwits-meta-image.png" data-next-head=""/><meta property="og:description" content="Track Anavex Life Sciences Corporation (AVXL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors" data-next-head=""/><meta name="description" content="Track Anavex Life Sciences Corporation (AVXL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors" data-next-head=""/><meta name="twitter:description" content="Track Anavex Life Sciences Corporation (AVXL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors" data-next-head=""/><meta property="og:keywords" content="Anavex Life Sciences Corporation stock price, Anavex Life Sciences Corporation, AVXL, AVXL stock price today, AVXL chart, AVXL quote, AVXL messages, AVXL discussion, AVXL community, AVXL news, AVXL message board" data-next-head=""/><meta name="keywords" content="Anavex Life Sciences Corporation stock price, Anavex Life Sciences Corporation, AVXL, AVXL stock price today, AVXL chart, AVXL quote, AVXL messages, AVXL discussion, AVXL community, AVXL news, AVXL message board" data-next-head=""/><link rel="canonical" href="https://stocktwits.com/symbol/AVXL" data-next-head=""/><script data-next-head="">window.performance.mark('chartiq-start');</script><script id="js-chartiq" type="module" async="" data-next-head="">import {CIQ} from '/_assets/stocktwits-chartiq-8.2.0-9c946a38/js/advanced.js';Object.assign(window,{CIQ});if(window.setChartiqJsStatus){window.setChartiqJsStatus(true)};</script><script id="corporation-schema" type="application/ld+json">{ "@context":"http://schema.org", "@type":"Corporation", "name":"AVXL", "url":"https://stocktwits.com/symbol/AVXL", "tickerSymbol": "AVXL" }</script><script id="webpage-schema" type="application/ld+json">{ "@context":"http://schema.org", "description":"Track Anavex Life Sciences Corporation (AVXL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors", "@type":"WebPage", "name":"Anavex Life Sciences Corporation (AVXL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News", "url":"https://www.stocktwits.com/symbol/AVXL", "speakable":{ "@type":"SpeakableSpecification", "cssSelector":["Title"] } }</script><script id="SiteNavigationElement" type="application/ld+json">{"@context":"https://schema.org","@type":"SiteNavigationElement","about":{"@type":"Thing","name":"Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY."},"hasPart":[{"@type":"SiteNavigationElement","name":"News","url":"https://stocktwits.com/symbol/AVXL/news"},{"@type":"SiteNavigationElement","name":"Sentiment","url":"https://stocktwits.com/symbol/AVXL/sentiment"},{"@type":"SiteNavigationElement","name":"About","url":"https://stocktwits.com/symbol/AVXL/about"},{"@type":"SiteNavigationElement","name":"Earnings","url":"https://stocktwits.com/symbol/AVXL/earnings"},{"@type":"SiteNavigationElement","name":"Fundamentals","url":"https://stocktwits.com/symbol/AVXL/fundamentals"}],"mainEntityOfPage":{"@id":"https://stocktwits.com/symbol/AVXL","@type":"WebPage"},"name":"Anavex Life Sciences Corporation","url":"https://stocktwits.com/symbol/AVXL"}</script><script id="BreadcrumbListSchema" type="application/ld+json" data-next-head="">{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","item":"https://stocktwits.com/","name":"home","position":1},{"@type":"ListItem","item":"https://stocktwits.com/symbol","name":"Symbol","position":2},{"@type":"ListItem","name":"AVXL","position":3}]}</script><meta name="apple-itunes-app" content="app-id=389157776"/><meta name="apple-mobile-web-app-title" content="Stocktwits"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="HandheldFriendly" content="true"/><link rel="preconnect" href="//cdn.cookielaw.org"/><link rel="dns-prefetch" href="//cdn.cookielaw.org"/><link rel="preconnect" href="https://api.stocktwits.com/api/2/" crossorigin=""/><link rel="preconnect" href="https://ql.stocktwits.com/" crossorigin=""/><link rel="preconnect" href="https://a.pub.network/" crossorigin=""/><link rel="preconnect" href="https://b.pub.network/" crossorigin=""/><link rel="preconnect" href="https://c.pub.network/" crossorigin=""/><link rel="preconnect" href="https://d.pub.network/" crossorigin=""/><link rel="preconnect" href="https://c.amazon-adsystem.com" crossorigin=""/><link rel="preconnect" href="https://s.amazon-adsystem.com" crossorigin=""/><link rel="preload" as="script" href="https://securepubads.g.doubleclick.net/tag/js/gpt.js"/><link rel="preload" as="script" href="https://d3lcz8vpax4lo2.cloudfront.net/ads-code/6f83f478-eee3-4828-b55c-3385e33fc440.js"/><link rel="preconnect" href="https://btloader.com/" crossorigin=""/><link rel="preconnect" href="https://api.btloader.com/" crossorigin=""/><link rel="preconnect" href="https://confiant-integrations.global.ssl.fastly.net" crossorigin=""/><script id="js-consent-defaults" type="text/javascript" charSet="UTF-8"> // Define dataLayer and the gtag function. window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} // Default ad_storage to 'denied'. gtag('consent', 'default', { ad_storage: "granted", analytics_storage: "granted", functionality_storage: "granted", personalization_storage: "granted", security_storage: "granted", ad_user_data: "granted", ad_personalization: "granted", 'wait_for_update': 500 }); </script><script id="js-gtm-config" type="text/javascript" charSet="UTF-8">window.dataLayer.push({"userGroup":"Unregistered","userType":"Unregistered"})</script><script id="js-gtm-script" type="text/javascript" charSet="UTF-8"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-PW9TNB7'); </script><script id="js-onetrust-script" src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" type="text/javascript" charSet="UTF-8" data-domain-script="bb67a836-2a23-4b28-ae7c-f69a7b7da25c"></script><script id="js-optanon-init" type="text/javascript">function OptanonWrapper() {}</script><script src="https://cdn.cookielaw.org/opt-out/otCCPAiab.js" type="text/javascript" charSet="UTF-8" ccpa-opt-out-ids="C0004" ccpa-opt-out-geo="us" ccpa-opt-out-lspa="true"></script><script id="js-pbjs-init" type="text/javascript">var pbjs = pbjs || {}; pbjs.que = pbjs.que || []; pbjs.que.push(function() { pbjs.setConfig({ consentManagement: { gdpr: { cmpApi: 'iab', allowAuctionWithoutConsent: false, timeout: 3000 }, } }); }); </script><script async="" src="https://scripts.webcontentassessor.com/scripts/6c1ba5ce9e1f02fc3536a598c46ccac36d5cdd2f907847c1ad0b2aa6a4917f03" type="application/javascript"></script><script src="https://chunks-prd.stocktwits-cdn.com/js/asc.stocktwits.js" async=""></script><script type="text/javascript">window.googletag = window.googletag || {cmd: []}; googletag.cmd.push(function() { googletag.pubads().setTargeting('domain', window.location.hostname); googletag.pubads().setTargeting('path', window.location.pathname); googletag.pubads().setTargeting('env', 'production'); })</script><script async="" defer="" src="https://launchpad-wrapper.privacymanager.io/e031648f-6de6-4093-9197-8082b9e79535/launchpad-liveramp.js"></script><link rel="dns-prefetch" href="https://api.stocktwits.com/api/2/"/><link rel="dns-prefetch" href="https://ql.stocktwits.com/"/><link rel="dns-prefetch" href="https://charts.stocktwits-cdn.com/cdn-cgi/image/"/><link rel="dns-prefetch" href="https://sih-st-charts.stocktwits-cdn.com/"/><link rel="dns-prefetch" href="https://avatars.stocktwits-cdn.com/cdn-cgi/image/"/><link rel="dns-prefetch" href="https://sih-st-avatars.stocktwits-cdn.com/"/><link rel="dns-prefetch" href="//fonts.googleapis.com"/><link rel="dns-prefetch" href="//live.primis.tech"/><link rel="dns-prefetch" href="//ads.pubmatic.com"/><link rel="dns-prefetch" href="//securepubads.g.doubleclick.net"/><link rel="preload" as="font" href="/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-600.woff2" crossorigin="anonymous"/><link rel="preload" as="font" href="/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-700.woff2" crossorigin="anonymous"/><link rel="preload" as="font" href="/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-regular.woff2" crossorigin="anonymous"/><link rel="apple-touch-icon" sizes="180x180" href="/apple-touch-icon.png"/><link rel="icon" href="/favicon.png?cb=1713811200000"/><link rel="icon" href="/favicon-16x16.png?cb=1713811200000" sizes="16x16"/><link rel="icon" href="/favicon-32x32.png?cb=1713811200000" sizes="32x32"/><meta property="og:site_name" content="Stocktwits"/><meta property="og:type" content="article"/><meta name="Author" content="StockTwits Inc (stocktwits.com)"/><meta name="Copyright" content="StockTwits"/><meta name="application-name" content="Stocktwits"/><meta name="google-site-verification" content="aKYidXr1_551Wb1zJeekLePBo4681p_VKVnkFKPehkw"/><meta name="y_key" content="80f3fdc8ba1b0d33"/><meta name="msvalidate.01" content="C1713B1F6321F08D4DB6862D229ACDFE"/><meta property="fb:admins" content="687256873"/><meta property="fb:app_id" content="138643396152005"/><style type="text/css">@font-face{font-display:swap;font-family:"Source Sans Pro";font-style:normal;font-weight:400;src:url(/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-regular.woff2)format("woff2"),url(/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-regular.woff)format("woff")}@font-face{font-display:swap;font-family:"Source Sans Pro";font-style:normal;font-weight:600;src:url(/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-600.woff2)format("woff2"),url(/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-600.woff)format("woff")}@font-face{font-display:swap;font-family:"Source Sans Pro";font-style:normal;font-weight:700;src:url(/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-700.woff2)format("woff2"),url(/_assets/a3a5f5442fc38e545ed15708628baa15/fonts/source-sans-pro-v19-latin-ext_latin-700.woff)format("woff")}</style><script> var _sift = window._sift = window._sift || []; _sift.push(['_setAccount', 'a8a3203b2d']); _sift.push(['_setSessionId', '94f33d022b9ea999a858eb0d2c04b4c1bb316147391593a7fe95f3585ebd6ca6']); _sift.push(['_trackPageview']); (function() { function ls() { var e = document.createElement('script'); e.src = 'https://cdn.siftscience.com/s.js'; document.body.appendChild(e); } if (window.attachEvent) { window.attachEvent('onload', ls); } else { window.addEventListener('load', ls, false); } })(); </script><script>try{window.sessionStorage.sid='94f33d022b9ea999a858eb0d2c04b4c1bb316147391593a7fe95f3585ebd6ca6'}catch(e){}</script><script id="js-mparticle" type="text/javascript"> window.mParticle = { config: { isDevelopmentMode: false } }; (function(t){window.mParticle=window.mParticle||{};window.mParticle.EventType={Unknown:0,Navigation:1,Location:2,Search:3,Transaction:4,UserContent:5,UserPreference:6,Social:7,Other:8};window.mParticle.eCommerce={Cart:{}};window.mParticle.Identity={};window.mParticle.config=window.mParticle.config||{};window.mParticle.config.rq=[];window.mParticle.config.snippetVersion=2.2;window.mParticle.ready=function(t){window.mParticle.config.rq.push(t)};var e=["endSession","logError","logBaseEvent","logEvent","logForm","logLink","logPageView","setSessionAttribute","setAppName","setAppVersion","setOptOut","setPosition","startNewSession","startTrackingLocation","stopTrackingLocation"];var o=["setCurrencyCode","logCheckout"];var i=["identify","login","logout","modify"];e.forEach(function(t){window.mParticle[t]=n(t)});o.forEach(function(t){window.mParticle.eCommerce[t]=n(t,"eCommerce")});i.forEach(function(t){window.mParticle.Identity[t]=n(t,"Identity")});function n(e,o){return function(){if(o){e=o+"."+e}var t=Array.prototype.slice.call(arguments);t.unshift(e);window.mParticle.config.rq.push(t)}}var mp=document.createElement("script");mp.type="text/javascript";mp.async=true;mp.src="https://stocktwits.com/_next/static/mparticle.js";var c=document.getElementsByTagName("script")[0];c.parentNode.insertBefore(mp,c)})('d2903ad31ed42949872c8a9470b8049e'); </script><script src="https://btloader.com/tag?o=5070086696337408&amp;upapi=true" async=""></script><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/ea717293f3f50388.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/ea717293f3f50388.css" crossorigin="anonymous" data-n-g=""/><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/510f27844c09fcbc.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/510f27844c09fcbc.css" crossorigin="anonymous" data-n-p=""/><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/5132dac7171d5836.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/5132dac7171d5836.css" crossorigin="anonymous"/><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/8cdd722dd25b3d1b.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/8cdd722dd25b3d1b.css" crossorigin="anonymous"/><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/8f5e2933eb0481c0.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/8f5e2933eb0481c0.css" crossorigin="anonymous"/><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/efa7a0535ff9f756.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/efa7a0535ff9f756.css" crossorigin="anonymous"/><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/ef46db3751d8e999.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/ef46db3751d8e999.css" crossorigin="anonymous"/><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/68026dabf82f447d.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/68026dabf82f447d.css" crossorigin="anonymous"/><link rel="preload" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/278014a282c3af83.css" as="style" crossorigin="anonymous"/><link rel="stylesheet" href="https://chunks-prd.stocktwits-cdn.com/_next/static/css/278014a282c3af83.css" crossorigin="anonymous"/><noscript data-n-css=""></noscript><script defer="" crossorigin="anonymous" nomodule="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/polyfills-42372ed130431b0a.js"></script><script defer="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/8060-7c175cbfeb147e2e.js" crossorigin="anonymous"></script><script defer="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/7545.da5e6c1b145406c3.js" crossorigin="anonymous"></script><script defer="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/8489-ac84f58fa63631a3.js" crossorigin="anonymous"></script><script defer="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/9500.8a51c9595c08e73c.js" crossorigin="anonymous"></script><script defer="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/1091.3d6dcc33f5fce865.js" crossorigin="anonymous"></script><script defer="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/9465.b025348158277ee3.js" crossorigin="anonymous"></script><script defer="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/1499.387525e75f09932b.js" crossorigin="anonymous"></script><script defer="" src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/1643.8ee6d461681a49b8.js" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/webpack-475c1ab3467cb719.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/framework-dd253615bf3bcf2d.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/main-c14603b4733418bc.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/pages/_app-b0bb4c26ba16fa9a.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/2501-112b21b896197216.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/5294-fc3a5daed29d39a1.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/29-1165e58320352062.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/4149-e6059e1077e999f5.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/4901-d70edce39a744cd5.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/2563-d332687ceedc697e.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/2304-e548d07a1a8379e5.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/1403-1d68e39ccbdaad7b.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/1256-7e6e4b1001e89012.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/5964-4d2129e2465c80da.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/2598-7f399d2a9089cf58.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/1741-c60ddcb585989ce6.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/chunks/pages/symbol/%5Bsymbol%5D/%5B%5B...tab%5D%5D-e12bf4ce07eac435.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/Sywudl5heFtPLFfFDPbOW/_buildManifest.js" defer="" crossorigin="anonymous"></script><script src="https://chunks-prd.stocktwits-cdn.com/_next/static/Sywudl5heFtPLFfFDPbOW/_ssgManifest.js" defer="" crossorigin="anonymous"></script></head><body class="bg-primary-background !mt-0 symbol-active-tab-feed"><div id="__next"><div class="bg-primary-background"><div class="Layout_layoutContainer__NH7Il flex flex-row min-h-screen desktopXxl|mx-auto Layout_layoutBorder__qMIMd bg-primary-background border-x tabletSm-down|border-x-0 border-primary-hairline" id="Layout"><div class="Sidebar_sidebarContainer__ctxbC tabletMd-down|hidden min-h-screen w-full pt-[58px] self-stretch bg-primary-background" data-testid="sidebar-container"></div><div class="Main_main__3C253 min-h-screen w-full"><div class="MainHeader_mainHeader__L2Fez top-0 tabletMd-down|left-0 tabletMd-down|right-0 z-25 fixed bg-primary-background border-b border-primary-hairline tabletSm|dark|border-l tabletMd|border-l tabletSm-down|border-x-0 MainHeader_mainHeaderBorder__RIXJZ border-r border-primary-hairline" id="app-main-header"><div class="MainHeader_mobileHeaderContainer___mWoe tabletMd|hidden"><div class="MobileHeader_container__jMTt_ relative text-primary-text border-b border-primary-hairline tabletMd-down|h-[52px] h-full"><nav class="MobileHeader_nav__T_c0N w-full h-full flex flex-row justify-between pr-2 items-center"><span><button class="MobileHeader_navButton__g0EGn MobileHeader_navButtonBase__w6cJF h-[50px] flex justify-center items-center cursor-pointer w-[50px]"><svg width="100%" height="100%" viewBox="0 0 12 10" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="MobileHeader_icon__kG_Ap w-[17px] h-[13px]"><path d="M1 1.3999H18.8" stroke="currentColor" stroke-width="1.2" stroke-linecap="round"></path><path d="M1 9.3999H18.8" stroke="currentColor" stroke-width="1.2" stroke-linecap="round"></path></svg></button></span><div class="flex flex-row justify-between items-center flex"><a class="STButton_md__qsWaf text-[15px] px-5 gap-2 STButton_button__ObG_J h-[--size] inline-flex flex-row items-center justify-center border rounded-full font-semibold whitespace-nowrap STButton_black-secondary__xIxs1 bg-white text-black border-secondary-button-border dark|bg-transparent dark|text-white hover|!bg-light-grey-6 dark|hover|!bg-dark-grey-5 MobileHeader_useAppButton__x8iPf !h-[32px] !w-[100px] px-4 my-auto font-semibold mr-2" role="button" tabindex="0" type="button" href="https://stocktwits.onelink.me/NjIT/geja8ly0"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="mobile" class="svg-inline--fa fa-mobile MobileHeader_mobileIcon__tLrIo w-[17px] h-[13px] pr-1" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M80 48c-8.8 0-16 7.2-16 16V448c0 8.8 7.2 16 16 16H304c8.8 0 16-7.2 16-16V64c0-8.8-7.2-16-16-16H80zM16 64C16 28.7 44.7 0 80 0H304c35.3 0 64 28.7 64 64V448c0 35.3-28.7 64-64 64H80c-35.3 0-64-28.7-64-64V64zM160 400h64c8.8 0 16 7.2 16 16s-7.2 16-16 16H160c-8.8 0-16-7.2-16-16s7.2-16 16-16z"></path></svg>Use App</a><button class="MobileHeader_navMenuButton__521co MobileHeader_navButtonBase__w6cJF h-[50px] flex justify-center items-center cursor-pointer w-[35px]"><svg aria-hidden="true" focusable="false" data-prefix="fal" data-icon="magnifying-glass" class="svg-inline--fa fa-magnifying-glass " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M384 208A176 176 0 1 0 32 208a176 176 0 1 0 352 0zM343.3 366C307 397.2 259.7 416 208 416C93.1 416 0 322.9 0 208S93.1 0 208 0S416 93.1 416 208c0 51.7-18.8 99-50 135.3L507.3 484.7c6.2 6.2 6.2 16.4 0 22.6s-16.4 6.2-22.6 0L343.3 366z"></path></svg></button></div></nav><div class="MobileHeader_center__l_JVA absolute top-2/4 left-2/4 transform -translate-x-2/4 -translate-y-2/4 text-primary-text flex justify-center items-end cursor-pointer"><span class="absolute opacity-0 pointer-events-none">Stocktwits</span><a title="Stocktwits" class="MobileHeader_logoLink__1wldO block w-full h-full p-2" href="/"><svg width="100%" height="100%" viewBox="0 0 32 28" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_8680_547)"><path fill-rule="evenodd" clip-rule="evenodd" d="M8.43835 0.374634H29.818V0.375255C31.4269 0.375255 32.333 1.62625 31.8327 3.15452L26.4417 19.6217C26.0621 20.7813 24.7526 21.7307 23.532 21.7307H17.8413L7.84361 27.9106L9.86606 21.7307H2.15224C0.54355 21.7307 -0.36256 20.4797 0.13772 18.9514L5.52869 2.48361C5.90831 1.32401 7.21782 0.374634 8.43835 0.374634ZM20.3165 2.59513L18.82 4.5743C17.9663 4.57338 17.2605 4.57175 16.7138 4.57048C16.5421 4.5701 16.386 4.56971 16.2461 4.56945C13.0738 4.56089 10.8185 7.35907 11.7039 9.81416C12.0889 11.1591 13.6515 11.7941 14.8779 12.2925L14.8964 12.2999C15.1545 12.4046 15.3971 12.503 15.6099 12.6013C16.1784 12.8481 15.9633 13.6945 15.3424 13.6982C14.2449 13.7085 8.19588 13.7311 8.19588 13.7311L5.4818 17.3202H9.2007L7.70839 19.2933H11.4273L12.9196 17.3202H13.1469C13.4144 17.3214 13.691 17.3281 13.9738 17.3354C15.4795 17.3732 17.1339 17.414 18.2636 16.673C20.1472 15.5853 20.7169 13.6921 20.2672 12.0761H20.2666C19.8816 10.7305 18.319 10.0955 17.0926 9.59715L17.0604 9.58409C16.8081 9.48152 16.5703 9.3849 16.3612 9.28828C15.7927 9.04086 16.0078 8.19569 16.6287 8.19143C17.7262 8.18107 23.7752 8.15854 23.7752 8.15854L26.4893 4.56945C25.0463 4.57247 23.7265 4.5743 22.5389 4.57492L24.0366 2.59513H20.3165Z" fill="currentColor"></path></g><defs><clipPath id="clip0_8680_547"><rect width="32" height="28" fill="white"></rect></clipPath></defs></svg></a></div></div></div><div class="MainHeader_desktopHeaderContainer__sKsDd hidden tabletMd|block border-primary-hairline border-b"><div class="DesktopHeader_container__4nFE3 flex flex-row justify-between items-center h-[50px] gap-x-5 tabletXxl|gap-x-8 px-5 max-w-[1340px]"><div class="w-full"><div class="DesktopHeader_search__9FdhP relative z-10 w-full max-w-[400px] min-w-[360px] DesktopHeader_transition__0b3LE transition-all duration-150 ease-in-out"></div></div><div class="DesktopHeader_nav___J3Kw flex flex-row justify-end items-center"><ul class="SiteNav_navbar__LXGWZ flex flex-row justify-end gap-x-[32px]"><li class="SiteNav_navbarLink__dEMWl SiteNav_link__n2uAf items-center text-primary-text inline-flex justify-between tabletMd-down|mr-5 tabletMd-down|border-b tabletMd-down|border-sitenav-border SiteNav_linkWithFontSize__K1HuW text-[13px]" data-testid="markets-site-nav-link"><a class="SiteNav_linkText__Bgfr8 tabletSm|text-right block" href="/sentiment">Trending</a></li><li class="SiteNav_navbarLink__dEMWl SiteNav_link__n2uAf items-center text-primary-text inline-flex justify-between tabletMd-down|mr-5 tabletMd-down|border-b tabletMd-down|border-sitenav-border SiteNav_linkWithFontSize__K1HuW text-[13px]"><a class="SiteNav_linkText__Bgfr8 tabletSm|text-right block" href="/news-articles">News</a></li><li class="SiteNav_navbarLink__dEMWl SiteNav_link__n2uAf items-center text-primary-text inline-flex justify-between tabletMd-down|mr-5 tabletMd-down|border-b tabletMd-down|border-sitenav-border SiteNav_linkWithFontSize__K1HuW text-[13px]"><a class="SiteNav_linkText__Bgfr8 tabletSm|text-right block" href="/sentiment/calendar">Earnings</a></li><li class="SiteNav_navbarLink__dEMWl SiteNav_link__n2uAf items-center text-primary-text inline-flex justify-between tabletMd-down|mr-5 tabletMd-down|border-b tabletMd-down|border-sitenav-border SiteNav_linkWithFontSize__K1HuW text-[13px]"><a class="SiteNav_linkText__Bgfr8 tabletSm|text-right block" target="_blank" href="https://www.stocktwits.com/newsletters">Newsletters</a></li><li class="SiteNav_navbarLink__dEMWl SiteNav_link__n2uAf items-center text-primary-text inline-flex justify-between tabletMd-down|mr-5 tabletMd-down|border-b tabletMd-down|border-sitenav-border SiteNav_linkWithFontSize__K1HuW text-[13px]"><a class="SiteNav_linkText__Bgfr8 tabletSm|text-right block" target="_blank" href="https://stocktwits.com/about/contact/?subject=Advertising%20Inquiries">Advertise</a></li></ul></div></div></div><div class="MainHeader_secondaryHeaderContainer__G0oQ4 border-t-0"><div class="Trending_content__pmtf9 Trending_container__6jqOE flex items-center justify-between overflow-hidden whitespace-nowrap font-semibold text-xs tabletSm|py-2.5 py-2.5" data-testid="trending-view"><div class="whitespace-pre-wrap"></div><div class="Trending_indicesShort__K_CXM flex flex-row items-center justify-between tabletSm|justify-between pl-5 pr-4 tabletSm-down|uppercase tabletSm-down|grow Trending_indicesShortUS__nOSfR w-[260px] Trending_disabledMarquee__6ilIf"><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/DIA"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">DIA</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">5.26%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/SPY"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">SPY</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">5.77%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/QQQ"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">QQQ</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">6.44%</span></span></span></div></a></div><div class="Trending_trending__DXWES tabletSm-down|flex w-full flex-row grow-[2] gap-x-[15px] pr-6 border-l border-primary-hairline contents tabletSm-down|hidden"><div class="flex flex-row justify-between items-center mr-2"><div class="Trending_trendingLabel__2JYHk tabletSm-down|hidden uppercase tabletSm|flex items-center Trending_updatedTrendingLabel__nZod8 text-[9px]"><span>Trending</span><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="circle-info" class="svg-inline--fa fa-circle-info Disclosures_icon__sUHXX ml-1 cursor-pointer !text-[12px]" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M256 48a208 208 0 1 1 0 416 208 208 0 1 1 0-416zm0 464A256 256 0 1 0 256 0a256 256 0 1 0 0 512zM216 336c-13.3 0-24 10.7-24 24s10.7 24 24 24h80c13.3 0 24-10.7 24-24s-10.7-24-24-24h-8V248c0-13.3-10.7-24-24-24H216c-13.3 0-24 10.7-24 24s10.7 24 24 24h24v64H216zm40-144a32 32 0 1 0 0-64 32 32 0 1 0 0 64z"></path></svg></div></div><div class="flex overflow-hidden"><div class="Trending_tickersRowAnimation__TbhYQ Trending_tickers__QRjxC flex mr-2 Trending_enabledMarquee___Zas5"><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/FARTCOIN.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><img alt="Top trending ticker" class="inline" height="12" src="https://chunks-prd.stocktwits-cdn.com/_next/static/media/hot.d13a6f1f.svg" width="10"/><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">FARTCOIN.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">0.07%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/SAFEMOON.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">SAFEMOON.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_neutral__yYNgH Change_container__GNa_f inline-flex gap-1" aria-label="Change"><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">0.00%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/GC.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">GC.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">24.05%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/COHU"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">COHU</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">10.18%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/ETF500.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">ETF500.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">15.22%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/AERGO.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">AERGO.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">31.17%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/BTC"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">BTC</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">2.16%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/NTRP"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">NTRP</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">7.25%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/CPRI"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">CPRI</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">2.72%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/SILJ"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">SILJ</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">10.52%</span></span></span></div></a></div><div class="Trending_tickersRowAnimation__TbhYQ Trending_tickers__QRjxC flex mr-2 Trending_enabledMarquee___Zas5"><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/FARTCOIN.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><img alt="Top trending ticker" class="inline" height="12" src="https://chunks-prd.stocktwits-cdn.com/_next/static/media/hot.d13a6f1f.svg" width="10"/><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">FARTCOIN.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">0.07%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/SAFEMOON.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">SAFEMOON.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_neutral__yYNgH Change_container__GNa_f inline-flex gap-1" aria-label="Change"><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">0.00%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/GC.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">GC.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">24.05%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/COHU"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">COHU</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">10.18%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/ETF500.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">ETF500.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">15.22%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/AERGO.X"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">AERGO.X</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">31.17%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/BTC"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">BTC</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">2.16%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/NTRP"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">NTRP</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_positive__2H4d1 Change_container__GNa_f inline-flex gap-1 text-green text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-up-long" class="svg-inline--fa fa-arrow-up-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M214.6 9.4c-12.5-12.5-32.8-12.5-45.3 0l-128 128c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 109.3V480c0 17.7 14.3 32 32 32s32-14.3 32-32V109.3l73.4 73.4c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-128-128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">7.25%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/CPRI"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">CPRI</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">2.72%</span></span></span></div></a><a class="Trending_ticker__j67AD pl-[11px] first|pl-0 first|mr-2" href="/symbol/SILJ"><div class="Trending_tickerLabel__4iKnb flex gap-x-1 text-primary-text"><span class="Trending_tickerName__Qgolo tabletMd-down|inline-block tabletMd-down|mr-0.25">SILJ</span><span class="Trending_tickerChange__n6QUj block h-[16px]"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red text-[9px]" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span class="Change_amount__l5O_n whitespace-nowrap" aria-label="Change">10.52%</span></span></span></div></a></div></div><div class="flex flex-row justify-center items-center cursor-pointer Trending_marqueeToggle__P6j2f cursor-pointer !w-6 !h-6 !max-w-6 !max-h-6 rounded-full border border---primary-border dark|border-primary-hairline px-2 mx-3 !text-[10px]"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="play" class="svg-inline--fa fa-play Trending_marqueeButton__y9GHY cursor-pointer text-primary-text Trending_playIcon__wJdbb ml-[2px]" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M73 39c-14.8-9.1-33.4-9.4-48.5-.9S0 62.6 0 80V432c0 17.4 9.4 33.4 24.5 41.9s33.7 8.1 48.5-.9L361 297c14.3-8.7 23-24.2 23-41s-8.7-32.2-23-41L73 39z"></path></svg><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="pause" class="svg-inline--fa fa-pause Trending_marqueeButton__y9GHY cursor-pointer text-primary-text Trending_pauseIcon__fXShN" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512"><path fill="currentColor" d="M48 64C21.5 64 0 85.5 0 112V400c0 26.5 21.5 48 48 48H80c26.5 0 48-21.5 48-48V112c0-26.5-21.5-48-48-48H48zm192 0c-26.5 0-48 21.5-48 48V400c0 26.5 21.5 48 48 48h32c26.5 0 48-21.5 48-48V112c0-26.5-21.5-48-48-48H240z"></path></svg></div><div class="mr-2"><a class="Trending_more__C6Qly tabletSm-down|hidden flex font-normal items-center gap-1 bg-primary-background text-primary-text" data-testid="trending-view-more-button" href="/sentiment/trending">More<svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-right" class="svg-inline--fa fa-chevron-right Trending_moreIcon__D_foA tabletSm-down|hidden text-primary-text text-xxs" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512"><path fill="currentColor" d="M310.6 233.4c12.5 12.5 12.5 32.8 0 45.3l-192 192c-12.5 12.5-32.8 12.5-45.3 0s-12.5-32.8 0-45.3L242.7 256 73.4 86.6c-12.5-12.5-12.5-32.8 0-45.3s32.8-12.5 45.3 0l192 192z"></path></svg></a></div></div></div></div></div><div class="Body_container__f_XJ0 flex flex-column desktopXxl|pr-0 Body_containerBorder__3T8GJ border-primary-hairline border-l tabletSm-down|border-x-0"><div class="Body_content__07Yri w-full max-w-[980px] tabletMd-down|max-w-none"><div class="SymbolPage_container__tRK07 tabletMd|max-w-[970px] w-full grid gap-2.5"><div class="SymbolPage_symbolPageBorder__gg8Gr border-primary-hairline border-r"><div class="SymbolPageHero_container__P6ghF mb-2.5 tabletSm-down|mb-0 tabletSm|p-2.5 tabletMd|p-0 tabletMd|mb-2.5 tabletMd|max-w-[660px]"><div></div><div class="Pod_container__AI83J bg-primary-background text-primary-text rounded-md"><div class="flex flex-row justify-start items-center Breadcrumbs_breadcrumbs__Rczip gap-2 tabletSm-down|gap-1 tabletSm-down|text-xxs h-8 px-4 tabletSm|px-5 text-st-tertiary-text text-xs w-full border-primary-hairline border-b overflow-x-auto scrollbar-hidden"><a class="shrink-0" href="/"><span class="Breadcrumbs_breadcrumbsLink__sisdv hover|underline hover|text-st-primary-text cursor-pointer capitalize">home</span></a><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="chevron-right" class="svg-inline--fa fa-chevron-right fa-sm Breadcrumbs_chevronRight__Ifb18 mx-1 pt-[1px]" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512"><path fill="currentColor" d="M305 239c9.4 9.4 9.4 24.6 0 33.9L113 465c-9.4 9.4-24.6 9.4-33.9 0s-9.4-24.6 0-33.9l175-175L79 81c-9.4-9.4-9.4-24.6 0-33.9s24.6-9.4 33.9 0L305 239z"></path></svg><a class="shrink-0" href="/symbol"><span class="Breadcrumbs_breadcrumbsLink__sisdv hover|underline hover|text-st-primary-text cursor-pointer capitalize">Symbol</span></a><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="chevron-right" class="svg-inline--fa fa-chevron-right fa-sm Breadcrumbs_chevronRight__Ifb18 mx-1 pt-[1px]" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512"><path fill="currentColor" d="M305 239c9.4 9.4 9.4 24.6 0 33.9L113 465c-9.4 9.4-24.6 9.4-33.9 0s-9.4-24.6 0-33.9l175-175L79 81c-9.4-9.4-9.4-24.6 0-33.9s24.6-9.4 33.9 0L305 239z"></path></svg><span class="capitalize shrink-0">AVXL</span></div><div class="SymbolPageHero_head__SRDI5 SymbolPageHero_grid__xbZvk grid tabletSm|px-5 tabletSm|py-2"><div class="SymbolPageHero_lede__LS_6R"><div class="SymbolInfo_container__wI07q flex flex-col"><div class="SymbolInfo_content__n_HwR"><div class="SymbolInfo_info__AFfk4 flex justify-between tabletMd|items-center tabletSm-down|px-4"><div class="SymbolLede_container__tlm6Y w-full flex flex-row items-center justify-between pb-2"><h1><div class="flex flex-row justify-start items-center gap-x-2 py-0.5"><span class="SymbolLede_label__SmBPZ block font-bold !text-[17px] leading-[22px] tabletSm-down|pt-2" data-testid="symbol-text">AVXL </span></div><span class="SymbolLede_title__O8aWL block text-tertiary-text text-xs font-normal tabletSm-down|max-w-[200px]">Anavex Life Sciences Corporation</span></h1><div class="SymbolLede_buttons__frYVl flex flex-row gap-2 items-center tabletMd-down|mt-2.5"><div class="SymbolLede_watch__R83q9 flex"><div class="SymbolWatchers_container__5vi3I flex items-center gap-3"><span class="SymbolWatchers_watchers__sp1FU tabletSm-down|hidden inline-flex gap-1.5 items-center text-xs"><svg fill="none" height="100%" viewBox="0 0 12 12" width="100%" xmlns="http://www.w3.org/2000/svg" class="SymbolWatchers_icon__w3PFN w-[10px] h-[10px]"><circle cx="6" cy="3" r="2" stroke="currentcolor"></circle><path d="M1 11.5C1.62805 9.18934 3.62886 7.5 6 7.5C8.37114 7.5 10.3719 9.18934 11 11.5" stroke="currentcolor"></path></svg>22,921</span></div></div></div></div></div><div class="SymbolInfo_pricing__UbjwC pt-1 border-t border-primary-hairline flex justify-between items-center relative"></div><div class="SymbolInfo_pricing__UbjwC pt-1 border-t border-primary-hairline flex justify-between items-center relative border-none"><div class="SymbolPricing_container__7FqjG relative flex flex-row justify-between items-center w-full tabletSm|w-auto tabletSm-down|px-4"><div class="SymbolPricing_priceContainer__6OFmu"><div class="SymbolPricing_amountContainer__Hx2b0 flex flex-col gap-x-2"><div class="SymbolPricing_updatedAmountFont__3N7up text-[35px] font-normal SymbolPricing_amount__UX8jT text-[35px] leading-10 font-light mb-1 h-[36px]">$8.20</div><div class="SymbolPricing_changeContainer__lBLyv text-[13px] flex flex-row gap-x-1 mb-1 h-[17px] leading-[17px]"><span class="SymbolPricing_change__DzzzZ whitespace-nowrap"><span class="Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" aria-label="Change"><div class="flex flex-row justify-between items-end gap-0.5"><div class="flex flex-row justify-between items-center gap-1"><span class="Change_arrow__AjLH9 relative flex items-center Change_negative__3Cz_W Change_container__GNa_f inline-flex gap-1 text-red" role="presentation"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-down-long" class="svg-inline--fa fa-arrow-down-long " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512"><path fill="currentColor" d="M169.4 502.6c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 402.7 224 32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 370.7L86.6 329.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128z"></path></svg></span><span data-testid="stock-price-change">$0.10</span></div><div class="flex flex-row justify-between items-center gap-1"><span data-testid="stock-price-percent-change"> (1.20%)</span></div></div></span></span><span>Today</span></div></div></div><div><table class="SymbolPricingFundamentals_container__a5E1m text-xs text-dark-grey flex flex-col tabletSm|hidden"><tbody><tr class="SymbolPricingFundamentals_row__eVoxP flex justify-between"><td class="SymbolPricingFundamentals_title__ojEt4 mr-2">Watchers</td><td>22,921</td></tr></tbody></table></div></div></div></div></div></div></div><div class="flex flex-col justify-between items-center cursor-pointer FundamentalsDataSummary_container__riWEH mt-4 mx-5 px-4 tabletSm-down|mx-4 tabletSm-down|px-4 py-2 mb-4 border border-primary-border rounded-lg FundamentalsDataSummary_hoverState__sUhGl hover|bg-light-grey-6-rgba-50 dark|hover|bg-dark-grey-5 cursor-pointer"><div class="flex flex-row justify-between items-center w-full"><div class="flex flex-row justify-around items-center w-full"><div><div class="flex flex-col justify-between items-center"><span class="FundamentalsDataSummary_itemTitle__Z1vQw text-xs text-st-secondary-text">Mkt Cap</span><span class="FundamentalsDataSummary_itemValue__NfAfA text-sm">$696.68M</span></div></div><div><div class="flex flex-col justify-between items-center"><span class="FundamentalsDataSummary_itemTitle__Z1vQw text-xs text-st-secondary-text">Volume</span><span class="FundamentalsDataSummary_itemValue__NfAfA text-sm">1.48M</span></div></div><div><div class="flex flex-col justify-between items-center"><span class="FundamentalsDataSummary_itemTitle__Z1vQw text-xs text-st-secondary-text">52W High</span><span class="FundamentalsDataSummary_itemValue__NfAfA text-sm">$14.44</span></div></div><div><div class="flex flex-col justify-between items-center"><span class="FundamentalsDataSummary_itemTitle__Z1vQw text-xs text-st-secondary-text">52W Low</span><span class="FundamentalsDataSummary_itemValue__NfAfA text-sm">$3.25</span></div></div><div class="tabletSm-down|hidden"><div class="flex flex-col justify-between items-center"><span class="FundamentalsDataSummary_itemTitle__Z1vQw text-xs text-st-secondary-text">PE Ratio</span><span class="FundamentalsDataSummary_itemValue__NfAfA text-sm">-14.83</span></div></div></div><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-down" class="svg-inline--fa fa-chevron-down FundamentalsDataSummary_chevron__jnhnT w-[12px] ml-5" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M233.4 406.6c12.5 12.5 32.8 12.5 45.3 0l192-192c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L256 338.7 86.6 169.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l192 192z"></path></svg></div></div><div class="SymbolPageMainArticle_container__zplEs cursor-pointer px-5 mb-4 transition-all duration-300 ease-in-out overflow-hidden tabletSm-down|mt-4 tabletSm-down|px-4 max-h-40"><div class="SymbolPageMainArticle_inner__vzc8n w-full flex items-start self-stretch border border-primary-border pl-3 pr-2 py-2 rounded-lg gap-3 hover|bg-light-grey-6-rgba-50 dark|hover|bg-dark-grey-5"><div class="w-full flex flex-col"><span class="SymbolPageMainArticle_header__PLy85 self-stretch text-st-primary-text text-sm font-semibold line-clamp-2 pb-0.5"><svg aria-labelledby="SymbolPageMainArticle-header-aria" role="img" width="100%" height="40"><title id="SymbolPageMainArticle-header-aria">Loading...</title><rect role="presentation" x="0" y="0" width="100%" height="100%" clip-path="url(#SymbolPageMainArticle-header-diff)" style="fill:url(#SymbolPageMainArticle-header-animated-diff)"></rect><defs><clipPath id="SymbolPageMainArticle-header-diff"><rect y="6" x="-10" width="100%" height="8"></rect><rect y="26" x="-10" width="100%" height="8"></rect></clipPath><linearGradient id="SymbolPageMainArticle-header-animated-diff" gradientTransform="translate(-2 0)"><stop offset="0%" stop-color="var(--content-loader-background)" stop-opacity="1"></stop><stop offset="50%" stop-color="var(--content-loader-foreground)" stop-opacity="1"></stop><stop offset="100%" stop-color="var(--content-loader-background)" stop-opacity="1"></stop><animateTransform attributeName="gradientTransform" type="translate" values="-2 0; 0 0; 2 0" dur="1.2s" repeatCount="indefinite"></animateTransform></linearGradient></defs></svg></span><div class="flex flex-col justify-start items-start"><div class="flex flex-row justify-start items-center NewsItem_info__lsjJW text-st-tertiary-text text-xs whitespace-nowrap flex-wrap"><span class="mr-1"></span></div></div></div><svg aria-labelledby="SymbolPageMainArticle-image-aria" role="img" width="40" height="40"><title id="SymbolPageMainArticle-image-aria">Loading...</title><rect role="presentation" x="0" y="0" width="100%" height="100%" clip-path="url(#SymbolPageMainArticle-image-diff)" style="fill:url(#SymbolPageMainArticle-image-animated-diff)"></rect><defs><clipPath id="SymbolPageMainArticle-image-diff"><rect r="0" width="100%" height="40"></rect></clipPath><linearGradient id="SymbolPageMainArticle-image-animated-diff" gradientTransform="translate(-2 0)"><stop offset="0%" stop-color="var(--content-loader-background)" stop-opacity="1"></stop><stop offset="50%" stop-color="var(--content-loader-foreground)" stop-opacity="1"></stop><stop offset="100%" stop-color="var(--content-loader-background)" stop-opacity="1"></stop><animateTransform attributeName="gradientTransform" type="translate" values="-2 0; 0 0; 2 0" dur="1.2s" repeatCount="indefinite"></animateTransform></linearGradient></defs></svg></div></div><div><div><div id="symbol-page-hero-tabs" class="react-tabs__tab-list Tab_reactTabList__DlGgm border-t !h-10 border-primary-hairline text-tertiary-text SymbolPageHero_symbolPageHeroTabs__s3VCs justify-around bg-legacy-white-four dark|bg-tertiary-background"><div data-cy="about-tab" class="react-tabs__tab Tab_reactTab__AN_bb relative border-b-2 border-transparent bg-primary-background SymbolPageHero_tab___OATW !bg-emphasized-tab-background SymbolPageHero_tab-about__lvD4w"><div class="SymbolPageHero_noPadding__dFwEA"><a href="/symbol/AVXL/about" class="Tab_text__yKwPe text-sm font-semibold"><h2 class="SymbolPageHero_label__pWp6i font-semibold text-[13px] h-[17px] leading-[17px]">About</h2></a></div></div><span></span><div data-cy="feed-tab" class="react-tabs__tab Tab_reactTab__AN_bb relative border-b-2 border-transparent bg-primary-background SymbolPageHero_tab___OATW !bg-emphasized-tab-background SymbolPageHero_tab-feed__TPjt2"><div class="SymbolPageHero_noPadding__dFwEA"><a href="/symbol/AVXL" class="Tab_text__yKwPe text-sm font-semibold"><h2 class="SymbolPageHero_label__pWp6i font-semibold text-[13px] h-[17px] leading-[17px]">Feed</h2></a></div></div><span></span><div data-cy="news-tab" class="react-tabs__tab Tab_reactTab__AN_bb relative border-b-2 border-transparent bg-primary-background SymbolPageHero_tab___OATW !bg-emphasized-tab-background SymbolPageHero_tab-news__2_yPc"><div class="SymbolPageHero_noPadding__dFwEA"><a href="/symbol/AVXL/news" class="Tab_text__yKwPe text-sm font-semibold"><h2 class="SymbolPageHero_label__pWp6i font-semibold text-[13px] h-[17px] leading-[17px]">News</h2></a></div></div><span></span><div data-cy="sentiment-tab" class="react-tabs__tab Tab_reactTab__AN_bb relative border-b-2 border-transparent bg-primary-background SymbolPageHero_tab___OATW !bg-emphasized-tab-background SymbolPageHero_tab-sentiment__rTL7t"><div class="SymbolPageHero_noPadding__dFwEA"><a href="/symbol/AVXL/sentiment" class="Tab_text__yKwPe text-sm font-semibold"><h2 class="SymbolPageHero_label__pWp6i font-semibold text-[13px] h-[17px] leading-[17px]">Sentiment</h2></a></div></div><span></span><div data-cy="earnings-tab" class="react-tabs__tab Tab_reactTab__AN_bb relative border-b-2 border-transparent bg-primary-background SymbolPageHero_tab___OATW !bg-emphasized-tab-background SymbolPageHero_tab-earnings__XxMb3"><div class="SymbolPageHero_noPadding__dFwEA"><a href="/symbol/AVXL/earnings" class="Tab_text__yKwPe text-sm font-semibold"><h2 class="SymbolPageHero_label__pWp6i font-semibold text-[13px] h-[17px] leading-[17px]">Earnings</h2></a></div></div><span></span><div data-cy="fundamentals-tab" class="react-tabs__tab Tab_reactTab__AN_bb relative border-b-2 border-transparent bg-primary-background SymbolPageHero_tab___OATW !bg-emphasized-tab-background SymbolPageHero_tab-fundamentals__n0pH9"><div class="SymbolPageHero_noPadding__dFwEA"><a href="/symbol/AVXL/fundamentals" class="Tab_text__yKwPe text-sm font-semibold"><h2 class="SymbolPageHero_label__pWp6i font-semibold text-[13px] h-[17px] leading-[17px]">Fundamentals</h2></a></div></div><span></span></div><div><div class="SymbolPageHero_tabContent__OXeMQ hidden SymbolPageHero_aboutContent__rfdc4"></div><div class="SymbolPageHero_tabContent__OXeMQ hidden SymbolPageHero_feedContent__hrN9a"><script id="table-schema" type="application/ld+json">{ "@context": "https://schema.org", "@type": "Table", "about": "AVXL Fundamentals" }</script><span itemscope="" itemType="https://schema.org/DataFeed"><meta itemProp="name" content="Anavex Life Sciences Corporation (AVXL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News"/><meta itemProp="description" content="Track Anavex Life Sciences Corporation (AVXL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors"/><meta itemProp="keywords" content="Anavex Life Sciences Corporation stock price, Anavex Life Sciences Corporation, AVXL, AVXL stock price today, AVXL chart, AVXL quote, AVXL messages, AVXL discussion, AVXL community, AVXL news, AVXL message board"/><meta itemProp="dateModified" content="04/04/2025, 03:54:40 PM EDT"/><span itemType="https://schema.org/DataFeedItem" itemscope="" itemProp="dataFeedElement"><meta itemProp="dateModified" content="04/04/2025, 03:54:40 PM EDT"/><span itemscope="" itemProp="item" itemType="https://schema.org/Thing"><meta itemProp="name" content="Last Price"/><meta itemProp="sameAs" content="https://stocktwits.com/symbol/AVXL"/></span></span></span><div data-cy="symbol-page-hero-media"><div class="Chart_container__B5j4Y relative w-full pt-5 pb-2 tabletMd|min-w-[503px]"><div class="Loading_loading__e823d flex justify-center items-center Chart_loading__8LWA_ absolute inset-0 flex items-center justify-center backdrop-filter backdrop-blur-sm z-1" style="height:322px"><span class="Loading_loadingIcon__k8BrD flex justify-center items-center"><svg aria-hidden="true" focusable="false" data-prefix="fal" data-icon="spinner-third" class="svg-inline--fa fa-spinner-third " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M463.9 376c7.6 4.4 17.5 1.8 21.4-6.1c17.1-34.3 26.7-73 26.7-113.9C512 120 405.9 8.8 272 .5c-8.8-.5-16 6.7-16 15.5s7.2 15.9 16 16.6C388.2 40.8 480 137.7 480 256c0 35.1-8.1 68.3-22.5 97.9c-3.9 8-1.3 17.7 6.4 22.1z"></path></svg></span></div></div></div></div><div class="SymbolPageHero_tabContent__OXeMQ hidden SymbolPageHero_feedContent__hrN9a"></div><div class="SymbolPageHero_tabContent__OXeMQ hidden SymbolPageHero_feedContent__hrN9a"></div><div class="SymbolPageHero_tabContent__OXeMQ hidden SymbolPageHero_earningsContent__7UNcV"></div><div class="SymbolPageHero_tabContent__OXeMQ hidden SymbolPageHero_sentimentContent__nVVMH"></div><div class="SymbolPageHero_tabContent__OXeMQ hidden SymbolPageHero_fundamentalsContent__0Q3Cr"></div><div class="SymbolPageHero_tabContent__OXeMQ hidden SymbolPageHero_newsContent__IqYuY"></div></div></div></div></div></div><div class="SymbolPage_discussion__QZZgN"></div><div class="SymbolPage_feedContainer__9RhsB tabletSm|bg-primary-background tabletMd|bg-transparent"><div class="SymbolPage_feedGrid__faEen h-full tabletSm|mx-auto tabletMd|mx-0 max-w-[660px] mx-auto"><div><div id="symbol-page-above-streams-line" role="presentation"></div><div></div></div></div></div></div><div class="SymbolPage_sidebar__BMi4v tabletSm-down|hidden flex flex-col gap-2.5"><div role="presentation"><div class="NewsBucketCompact_container__w_DxG relative bg-primary-background text-primary-text overflow-hidden rounded-md pb-2 NewsBucketCompact_containerBorder__XpYYs border-primary-hairline border"><div class="NewsBucketCompactHeader_container__bYeeJ pt-4 pb-2 px-4 w-full flex justify-between items-center bg-primary-background text-primary-text text-sm"><h2 class="NewsBucketCompactHeader_title__PrvOb font-semibold">Latest AVXL News</h2><a class="NewsBucketCompactHeader_more__8_psJ cursor-pointer" href="/symbol/AVXL/news">View<svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="chevron-right" class="svg-inline--fa fa-chevron-right NewsBucketCompactHeader_icon__TttqM ml-1 text-xxs" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512"><path fill="currentColor" d="M305 239c9.4 9.4 9.4 24.6 0 33.9L113 465c-9.4 9.4-24.6 9.4-33.9 0s-9.4-24.6 0-33.9l175-175L79 81c-9.4-9.4-9.4-24.6 0-33.9s24.6-9.4 33.9 0L305 239z"></path></svg></a></div></div></div><div class="flex items-center justify-center"><div class="Primis_container__OlMHR overflow-hidden relative SymbolPage_primis__YHE0l invisible tabletMd|visible"><div class="flex flex-col"><div style="height:169px;width:300px"><div role="presentation"></div></div><p class="Disclosure_disclosure__GmLV4 Disclosure_disclosureCompact__7OUvM mx-auto text-center text-tertiary-text text-[10px] leading-[16px] pb-3">Advertisement.<span> <a class="Disclosure_removeAdsLink__3yG8W text-primary-text underline cursor-pointer" href="/subscriptions">Remove ads.</a></span></p></div></div></div><div class="relative Insticator_adClass__aZKoy min-h-[250px] z-1 leading-none"><div class="BackgroundLoaderAd_container__BFoDY overflow-hidden text-dark-grey-2 dark|text-grey-5 font-light rounded-md absolute top-0 right-0 bottom-0 left-0 flex items-center justify-center bg-transparent Insticator_loaderClass__mVUIh min-h-[250px] z-1 rounded-none"></div><div class="Insticator_adClass__aZKoy min-h-[250px] z-1 leading-none"></div></div><p class="Disclosure_disclosure__GmLV4 Disclosure_disclosureCompact__7OUvM mx-auto text-center text-tertiary-text text-[10px] leading-[16px] pb-3">Advertisement.<span> <a class="Disclosure_removeAdsLink__3yG8W text-primary-text underline cursor-pointer" href="/subscriptions">Remove ads.</a></span></p><div class="sticky-outer-wrapper"><div class="sticky-inner-wrapper" style="position:relative;top:0px"><div class="relative SidebarRightAd_adClass__7j2lf leading-none"><div class="BackgroundLoaderAd_container__BFoDY overflow-hidden text-dark-grey-2 dark|text-grey-5 font-light rounded-md absolute top-0 right-0 bottom-0 left-0 flex items-center justify-center bg-transparent SidebarRightAd_loaderClass__NUf_b z-[-1] rounded-none"></div><div class="SidebarRightAd_adClass__7j2lf leading-none"></div></div><p class="Disclosure_disclosure__GmLV4 Disclosure_disclosureCompact__7OUvM mx-auto text-center text-tertiary-text text-[10px] leading-[16px] pb-3">Advertisement.<span> <a class="Disclosure_removeAdsLink__3yG8W text-primary-text underline cursor-pointer" href="/subscriptions">Remove ads.</a></span></p></div></div></div></div></div></div></div></div></div><noscript><img src="//beacon.etfflows.com/piwik.php?idsite=35" style="border:0" alt=""/></noscript></div><script id="__NEXT_DATA__" type="application/json" crossorigin="anonymous">{"props":{"hasToken":false,"__N_SSP":true,"pageProps":{"hasToken":false,"initialData":{"id":12844,"symbol":"AVXL","symbolMic":"AVXL.XNAS","exchange":"NASDAQ","region":"US","title":"Anavex Life Sciences Corporation","aliases":[],"isFollowing":false,"watchlistCount":22921,"hasPricing":true,"instrumentClass":"Stock","liveEvent":false,"sector":"HealthTechnology","industry":"Biotechnology","logoUrl":"https://logos.stocktwits-cdn.com/placeholder.png","trending":false,"trendingScore":-1.33712,"trends":null,"tradeStatus":"FRACTIONAL","features":{"alertsPrice":true,"socialData":true,"trendingMessages":true,"earnings":true},"cusip":"032797300","isin":"US0327973006","shouldSeoIndex":true,"lastUpdated":"04/04/2025, 03:54:40 PM EDT","priceData":{"lastSize":131194,"previousClose":8.3,"outcome":"Success","extendedHoursPrice":8.2,"message":"Delay times are 15 mins for NASDAQ.","iSO8601":"2025-04-04T20:00:00Z","identifier":"AVXL","percentChange":-1.325,"change":-0.11,"previousCloseDate":"2025-04-03","high":8.39,"low":7.79,"volume":1483750,"extendedHoursChange":0.01,"extendedHoursDateTime":"2025-04-04 19:54:40","dateTime":"2025-04-04 16:00:00","uTCOffset":"-4","open":8.02,"type":"equity","extendedHoursType":"PostMarket","extendedHoursPercentChange":0.122,"symbol":"AVXL","last":8.19,"lastClose":"8.19","lastCloseTime":"2025-04-04 16:00:00"},"tradeButton":{"partnership":"etoro","buttonUrl":"https://logos.stocktwits-cdn.com/trade-button-etoro-3x.png","modalHtml":"\u003c!DOCTYPE html\u003e\n\u003chtml lang='en'\u003e\u003chead\u003e\u003cmeta charset='UTF-8'\u003e\u003cmeta content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' name='viewport'\u003e\u003ctitle\u003eDocument\u003c/title\u003e\u003c/head\u003e\u003cbody\u003e\u003cstyle\u003e\n .disclaimer {\n padding: 32px 20px;\n text-align: center;\n font-family: Source Sans Pro, Arial, Helvetica Neue, Helvetica, sans-serif;\n }\n .cancel {\n display: flex;\n justify-content: flex-end;\n }\n @media only screen and (max-width: 768px) {\n .disclaimer {\n max-width: 350px;\n margin:0 auto;\n }\n }\n .disclaimer h2 {\n font-size: 20px;\n font-weight: 700;\n line-height: 28px;\n }\n .disclaimer p {\n color: #636366;\n margin: 0 auto;\n width: 100%;\n max-width:295px;\n font-size: 14px;\n line-height: 20px;\n }\n .disclaimer .footer {\n color: #8e8e93;\n margin: 0 auto;\n width: 100%;\n max-width: 295px;\n font-weight: 700;\n font-size: 12px;\n line-height: 16px;\n }\n .header_image img {\n margin: 0 auto;\n width: 58.7;\n height: 18px;\n margin-bottom: 20px;\n }\n .center_image img {\n max-width: 100%;\n height: auto;\n object-fit: cover;\n }\n #trade_partnership_continue_btn {\n display: block;\n width: 100%;\n height: 40px;\n line-height: 40px;\n margin:20px 0;\n color: white;\n border-radius: 9999px;\n background: #13C636;\n }\n #trade_partnership_continue_btn:hover {\n background: #22EA49;\n }\n\u003c/style\u003e\u003cdiv class='disclaimer'\u003e\u003cdiv class='cancel'\u003e\u003ca href='https://www.etoro.com/markets/AVXL?utm_medium=Media%20Performance\u0026amp;utm_source=122986\u0026amp;utm_content=21403\u0026amp;st-action=cancel'\u003e\u003csvg fill='none' height='15' viewBox='0 0 14 15' width='14' xmlns='http://www.w3.org/2000/svg'\u003e\u003cpath d='M13.5742 2.63672L8.41797 7.79297L13.5312 12.9062C13.9609 13.293 13.9609 13.9375 13.5312 14.3242C13.1445 14.7539 12.5 14.7539 12.1133 14.3242L6.95703 9.21094L1.84375 14.3242C1.45703 14.7539 0.8125 14.7539 0.425781 14.3242C-0.00390625 13.9375 -0.00390625 13.293 0.425781 12.8633L5.53906 7.75L0.425781 2.63672C-0.00390625 2.25 -0.00390625 1.60547 0.425781 1.17578C0.8125 0.789062 1.45703 0.789062 1.88672 1.17578L7 6.33203L12.1133 1.21875C12.5 0.789062 13.1445 0.789062 13.5742 1.21875C13.9609 1.60547 13.9609 2.25 13.5742 2.63672Z' fill='#636366'\u003e\u003c/path\u003e\u003c/svg\u003e\u003c/a\u003e\u003c/div\u003e\u003cdiv class='header_image'\u003e\u003cimg alt='eToro logo' src='https://logos.stocktwits-cdn.com/etoro-logo-3x.png'\u003e\u003c/div\u003e\u003ch2\u003eTrade AVXL with eToro\u003c/h2\u003e\u003cp\u003eInvest with confidence on this and other assets through our partnership with eToro\u003c/p\u003e\u003cdiv class='center_image'\u003e\u003cimg alt='Trade with eToro candlestick chart' src='https://logos.stocktwits-cdn.com/etoro-modal-graphic-2x.png'\u003e\u003c/div\u003e\u003ca href='https://www.etoro.com/markets/AVXL?utm_medium=Media%20Performance\u0026amp;utm_source=122986\u0026amp;utm_content=21403\u0026amp;st-action=continue' id='trade_partnership_continue_btn' target='_blank'\u003eContinue to eToro\u003c/a\u003e\u003cp class='footer'\u003e\u003cdiv style='font-size: var(--bs-body-font-size);'\u003e\nFor illustration purposes only.\nYour capital is at risk.\n\u003c/div\u003e\u003c/p\u003e\u003c/div\u003e\u003c/body\u003e\u003c/html\u003e\n"},"discussions":{},"fundamentals":{"totalDebt":"0","grossIncomeMargin":"","totalEnterpriseValue":"341.91151832","totalExpenses":"52.877","ePS":"-0.5152","sharesHeldByInstitutions":"29.327628","earningsGrowth":"-3.0801","averageDailyVolumeLastMonth":"1084629.5714","dividendPayoutRatio":"","eBITDA":"","bookValuePerShare":"1.41827","5YearAveragePERatio":"","totalLiabilities":"15.304","lowPriceLast52Weeks":"3.25","numberOfEmployees":"42","symbol":"AVXL","beta":"1.8478","floatCurrent":"82.2567","totalAssets":"135.567","pERatio":"-14.83","industryName":"Biotechnology","enterpriseOverEBITDA":"","priceToBook":"6.2753","highPriceLast52Weeks":"14.4405","marketCapitalization":"696.6758","name":"Anavex Life Sciences Corporation","instrumentClass":"Stock","salesOrRevenue":"0","dividendsPerShareSecurity":"0","fiscalPeriodEndDate":"9/30/2024 12:00:00 AM","dividendExDate":"","businessDescription":"Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.","sectorName":"Health Technology","50DayMovingAverage":"8.8832","dividendRate":"0","pEGRatio":"","totalCash":"132.187","dividendYieldSecurity":"0","revenueToAssets":"0","lastUpdated":"04/06/2025","revenuePerEmployee":"0","sharesOutstanding":"84.795517","averageDailyVolumeLast3Months":"1280990.8065"},"quote":{"previousClose":8.3,"dateTime":"2025-04-04 16:00:00","uTCOffset":"-4","low":7.79,"extendedHoursPercentChange":0.122,"extendedHoursDateTime":"2025-04-04 19:54:40","type":"equity","outcome":"Success","extendedHoursPrice":8.2,"easternDateTime":"04/04/2025, 12:00:00 PM EDT","easternExtendedHoursDateTime":"04/04/2025, 03:54:40 PM EDT","symbol":"AVXL","previousCloseDate":"2025-04-03","volume":1483750,"lastSize":"131194","percentChange":-1.325,"change":-0.11,"last":8.19,"extendedHoursType":"PostMarket","iSO8601":"2025-04-04T20:00:00Z","high":8.39,"extendedHoursChange":0.01,"message":"Delay times are 15 mins for NASDAQ.","open":8.02},"articles":[{"author":{},"canonical_url":"https://www.youtube.com/watch?v=N-7z6xZV438","category":{"id":0},"content":"","created_at":"2025-01-16T02:00:00Z","headline":"Lightning Round: Sell Viking Therapeutics, says Jim Cramer","image_url":"","primary_symbol_code":"SRPT","sid":"chGtf1HbUUL8","source":{"id":723,"source_name":"CNBC Television-YouTube","url_domain":"CNBC Television-YouTube"},"subcategory":{"id":0},"summary":"'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, Transocean, and DuPont...","symbol_codes":["SRPT","AVXL","VKTX","RIG"],"tags":null,"type":"article","updated_at":"2025-01-16T07:02:01Z"},{"author":{"description":"Ramakrishnan is a senior writer at Stocktwits, the largest social network for investors and traders. He specializes in covering the US markets and writes extensively on stocks, commodities, ETFs, and other asset classes, with a soft spot for EV companies and Big Tech.","designation":"Senior Staff Writer","id":3,"name":"Ramakrishnan M","profile_avatar":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ram_author_image_resized_and_compressed_1_0022abb723.jpg","profile_link":"","social_media_links":{"facebook":"https://in.linkedin.com/in/ramakrishnan-m","twitter":"https://x.com/heyram27?lang=en","website":"https://stocktwits.com/BangaloreBidder"},"type":"Stocktwits"},"canonical_url":"","category":{"id":2,"name":"Markets"},"content":"\u003cp\u003eAnavex Life Sciences Corp., a small-cap biotech specializing in neurodegenerative and neurodevelopmental diseases, emerged as the top pick among retail investors in a recent Stocktwits poll.\u0026nbsp;\u003c/p\u003e\u003cp\u003eNearly 45% of respondents believe Anavex will outperform in the first quarter of 2025, compared to 33% for Novavax and 9% for Rigel Pharmaceuticals.\u003c/p\u003e\u003cp\u003e\u003cstembedurl\u003ehttps://stocktwits.com/StocktwitsPolls/message/599783274\u003c/stembedurl\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eAlzheimer’s Therapy Momentum\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eAnavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73), whose European Marketing Authorization Application was\u0026nbsp;\u003ca href=\"https://stocktwits.com/news-articles/markets/5/avxl-stock-rises-on-q4-results-ema-nod-for-blarcamesine/cJazDmdRj5\"\u003eaccepted\u003c/a\u003e last month.\u0026nbsp;\u003c/p\u003e\u003cp\u003ePromising trial results showed three years of continuous blarcamesine treatment significantly reduced clinical decline in early Alzheimer’s patients, with no safety issues reported.\u0026nbsp;\u003c/p\u003e\u003cp\u003eThat positions the drug as a potential breakthrough, especially as interest in Alzheimer’s therapies intensifies following recent setbacks for rivals like Cassava Sciences.\u003c/p\u003e\u003cp\u003eThe company’s stock surged over 76% in 2024 but is down 6% year-to-date, with a high short interest of 24.5% as per Koyfin data.\u0026nbsp;\u003c/p\u003e\u003cp\u003eAnavex reported $132.2 million in cash reserves as of Sept. 30, 2024, and projects a four-year cash runway at its current burn rate.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eVaccine Maker Eyes Recovery\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eNovavax has maintained momentum after a 68% gain in 2024, with shares up nearly 6% this year.\u0026nbsp;\u003c/p\u003e\u003cp\u003eThe company\u0026nbsp;\u003ca href=\"https://stocktwits.com/news-articles/markets/equity/nvax-stock-is-undervalued-say-retail-investors/chGWtkSRZy\"\u003erecovered\u003c/a\u003e from an FDA clinical hold on its COVID-19 and flu combination vaccine late last year, thanks to a $50 million milestone payment under its Sanofi partnership and increasing hopes for a bird flu vaccine.\u0026nbsp;\u003c/p\u003e\u003cp\u003eNovavax holds the largest market cap among the three at $1.38 billion. It has $909.5 million in cash and a manageable debt load of $262 million, which many retail investors see as an advantage.\u0026nbsp;\u003c/p\u003e\u003cp\u003eIt also has a high short interest of 24.5%.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eUnder-The-Radar Bet?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eRigel Pharmaceuticals focuses on autoimmune and hematologic diseases. The company recently received orphan drug designation for R289, a treatment for lower-risk myelodysplastic syndromes.\u0026nbsp;\u003c/p\u003e\u003cp\u003eA growing portfolio of approved therapies, such as TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for acute myeloid leukemia has also boosted retail sentiment.\u003c/p\u003e\u003cp\u003eOn Monday, the company said it expects fourth-quarter revenue of $57.6 million, up 61% year-over-year and above a Wall Street estimate of $47.4 million. It also projected 2025 revenue of $200-$210 million, better than an expected $193.5 million.\u003c/p\u003e\u003cp\u003eRigel’s stock rose 15% in 2024 and remained nearly flat in 2025. As of Dec. 31, 2024, it had estimated cash reserves of $77.3 million.\u0026nbsp;\u003c/p\u003e\u003cp\u003eRigel’s short interest is relatively low at 3.6%.\u003c/p\u003e\u003cp\u003e\u003ci\u003eFor updates and corrections, email newsroom[at]stocktwits[dot]com.\u003c/i\u003e\u003c/p\u003e","created_at":"2025-01-14T13:51:10Z","featured_image":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/alzheimers_illustration_resized_d887704099.jpg","featured_image_attributes":{"alt_text":"Anavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73). | Image source: Getty Images ","caption":"Anavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73). | Image source: Getty Images ","url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/alzheimers_illustration_resized_d887704099.jpg"},"headline":"Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz","image_url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/alzheimers_illustration_resized_d887704099.jpg","meta_description":"The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.","meta_keywords":"Anavex stock, Novavax stock, Rigel Pharmaceuticals stock, AVXL stock performance, NVAX stock, RIGL stock, Alzheimer’s therapy, blarcamesine, Novavax COVID vaccine, Rigel R289\n","meta_title":"Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz","primary_symbol_code":"AVXL","sid":"chG8L3WRNz","source":{"id":1071,"source_name":"Stocktwits","url_domain":"stocktwits.com"},"subcategory":{"id":3,"name":"Equity","parent_id":2},"summary":"The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.","symbol_codes":["AVXL","NVAX","RIGL"],"tags":[{"id":2,"tag_name":"Trending"},{"id":3,"tag_name":"Small Cap"},{"id":6,"tag_name":"Mid Cap"},{"id":10,"tag_name":"Retail"}],"type":"article","updated_at":"2025-01-14T13:51:10Z","url_slug":"retail-bets-avxl-stock-to-outperform-nvax-rigl-in-q1-2025"},{"author":{"description":"Ramakrishnan is a senior writer at Stocktwits, the largest social network for investors and traders. He specializes in covering the US markets and writes extensively on stocks, commodities, ETFs, and other asset classes, with a soft spot for EV companies and Big Tech.","designation":"Senior Staff Writer","id":3,"name":"Ramakrishnan M","profile_avatar":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ram_author_image_resized_and_compressed_1_0022abb723.jpg","profile_link":"","social_media_links":{"facebook":"https://in.linkedin.com/in/ramakrishnan-m","twitter":"https://x.com/heyram27?lang=en","website":"https://stocktwits.com/BangaloreBidder"},"type":"Stocktwits"},"canonical_url":"","category":{"id":2,"name":"Markets"},"content":"\u003cp\u003eAnavex Life Sciences Corp. shares rocketed over 27% on Monday, hitting their highest levels since February 2023, fueled by a mix of positive earnings results and regulatory progress in Europe.\u003c/p\u003e\u003cp\u003eThe biopharma company, focused on neurodegenerative and neurodevelopmental diseases, reported a fiscal fourth-quarter loss of $11.6 million, or an adjusted $0.14 per share, compared to a loss of $10.1 million in the year-ago period.\u0026nbsp;\u003c/p\u003e\u003cp\u003eWhile research and development (R\u0026amp;D) and overhead costs rose, the per-share loss was narrower than the FactSet consensus estimate of $0.16.\u003c/p\u003e\u003cp\u003eAnavex also highlighted a strong cash position, with $132.2 million in reserves, which the company says will provide a four-year runway at current burn rates.\u003c/p\u003e\u003cp\u003eCreating more buzz was news that the European Medicines Agency (EMA) accepted the Marketing Authorization Application for blarcamesine (ANAVEX 2-73), an investigational oral drug for Alzheimer’s disease.\u0026nbsp;\u003c/p\u003e\u003cp\u003eAnavex’s Head of R\u0026amp;D, Juan Carlos Lopez-Talavera, said: \"The EMA filing acceptance for blarcamesine to review the Marketing Authorization Application potentially brings us a step closer offering broader patient access to a new treatment option in Europe, and we look forward to continued engagement with the EMA.”\u003c/p\u003e\u003cp\u003eCEO Christoper Missling said, \"We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains deeply committed to executing on our momentum.”\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003cimg style=\"aspect-ratio:1326/1056;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_poll_sentiment_and_message_volume_Dec_24_fe40cd4f12.png\" alt=\"AVXL poll sentiment and message volume Dec 24.png\" width=\"1326\" height=\"1056\"\u003e\u003cfigcaption\u003eAVXL poll, sentiment and message volume on Dec 24 as of 1:30 pm ET | source: Stocktwits\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003eRetail investors on Stocktwits celebrated the news, with sentiment shifting sharply to ‘bullish’ from ‘neutral.’\u0026nbsp;\u003c/p\u003e\u003cp\u003eMany hailed the EMA filing as a significant milestone, with one user claiming very high approval rates by the European regulator for “accepted drug candidates in 2024 that aren't withdrawn.”\u003c/p\u003e\u003cp\u003e\u003cstembedurl\u003ehttps://stocktwits.com/Guzzi62/message/597573043\u003c/stembedurl\u003e\u003c/p\u003e\u003cp\u003e\u003cstembedurl\u003ehttps://stocktwits.com/PhillipHerass/message/597572113\u003c/stembedurl\u003e\u003c/p\u003e\u003cp\u003e\u003cstembedurl\u003ehttps://stocktwits.com/Logic102/message/597572650\u003c/stembedurl\u003e\u003c/p\u003e\u003cp\u003eAccording to a\u0026nbsp;\u003ca target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10499418/\"\u003estudy\u003c/a\u003e published last year in the Clinical and Translational Science, an official journal of the American Society for Clinical Pharmacology and Therapeutics, the EMA was found to have the highest approval rate (93.8%) for non-oncology products when compared with Swiss and U.S. regulators. The data analyzed decisions between 2009 and 2018 on new active substances.\u003c/p\u003e\u003cp\u003eThe broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences\u0026nbsp;\u003ca href=\"https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh\"\u003ereported\u003c/a\u003e disappointing results for its candidate simufilam last month.\u0026nbsp;\u003c/p\u003e\u003cp\u003eD. Boral Capital had noted Anavex’s neuroprotective mechanism could position blarcamesine as a superior option, reiterating a ‘Buy’ rating with a $46 price target.\u003c/p\u003e\u003cp\u003eAnavex shares are now up 88% year-to-date.\u003c/p\u003e\u003cp\u003e\u003ci\u003eFor updates and corrections, email newsroom[at]stocktwits[dot]com.\u003c/i\u003e\u003c/p\u003e","created_at":"2024-12-23T18:38:14Z","featured_image":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ema_logo_resized_d861912220.jpg","featured_image_attributes":{"alt_text":"EMA European Medicines Agency at Canary Wharf on 5th November 2024 in London, United Kingdom. (photo by Mike Kemp/In Pictures via Getty Images)","caption":"EMA European Medicines Agency at Canary Wharf on 5th November 2024 in London, United Kingdom. (photo by Mike Kemp/In Pictures via Getty Images)","url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ema_logo_resized_d861912220.jpg"},"headline":"Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer’s Drug: Retail’s Overjoyed","image_url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ema_logo_resized_d861912220.jpg","meta_description":"The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences reported disappointing results for its candidate simufilam last month.","meta_keywords":"anavex stock, anavex life sciences corp, anavex stock news, blarcamesine ANAVEX 2-73, anavex Alzheimer’s drug, EMA marketing authorization, anavex earnings","meta_title":"Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer’s Drug: Retail’s Overjoyed","primary_symbol_code":"AVXL","sid":"cJazDmdRj5","source":{"id":1071,"source_name":"Stocktwits","url_domain":"stocktwits.com"},"subcategory":{"id":3,"name":"Equity","parent_id":2},"summary":"The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences reported disappointing results for its candidate simufilam last month.","symbol_codes":["AVXL","SAVA"],"tags":[{"id":2,"tag_name":"Trending"},{"id":3,"tag_name":"Small Cap"},{"id":10,"tag_name":"Retail"}],"type":"article","updated_at":"2024-12-23T18:38:14Z","url_slug":"avxl-stock-rises-on-q4-results-ema-nod-for-blarcamesine"},{"author":{},"canonical_url":"https://www.investopedia.com/what-to-expect-in-the-markets-this-week-8764806","category":{"id":0},"content":"","created_at":"2024-12-22T10:00:00Z","headline":"What To Expect in the Markets This Week","image_url":"https://www.investopedia.com/thmb/8KjjKnI3T-oQpb8xmAsZ4vxjqro=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1448939835-eb50af7b74c1476cafcd8690ff13d246.jpg","primary_symbol_code":"AVXL","sid":"cJaDQVBbuLV0","source":{"id":378,"source_name":"Investopedia Headlines","url_domain":"Investopedia Headlines"},"subcategory":{"id":0},"summary":"Coming up: Shortened market hours around the Christmas holiday, consumer confidence, new home sales, initial jobless claimsGetty ImagesKey TakeawaysMarkets are closed Wednesday for Christmas.On...","symbol_codes":["AVXL"],"tags":null,"type":"article","updated_at":"2024-12-22T19:00:01Z"},{"author":{"description":"Frank MacArthur is from wealthyvc.com","designation":"Wealthy VC","id":7,"name":"Frank MacArthur","profile_avatar":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/wealthy_V_Cavatar_1524535e0c.jpg","profile_link":"wealthyvc.com","social_media_links":{"facebook":"","twitter":"","website":"wealthyvc.com"},"type":""},"canonical_url":"","category":{"id":2,"name":"Markets"},"content":"\u003cp\u003eThis Week’s Hottest Themes: Biotech (RFK Jr. Meddling), Space (Trump's Space Force),\u0026nbsp; AI (The Theme of the Year)\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003eWealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in sectors actively drawing capital. This targeted approach, combined with real-time news surveillance, helps us uncover stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.\u003c/p\u003e\u003cp\u003eHere's a list of today's most important names:\u003c/p\u003e\u003cp\u003e\u003cstrong\u003e1. Cassava Sciences (NASDAQ: SAVA)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer’s disease. Its investigational drug, Simufilam, has been central to its research efforts.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe\u003c/strong\u003e \u003cstrong\u003eNews\u003c/strong\u003e: Cassava's stock took a dramatic plunge after disappointing Phase 3 trial results for Simufilam, followed by a social media storm triggered by Martin Shkreli’s scathing critique of the drug’s efficacy. Shkreli, calling Simufilam’s mechanism “implausible,” encouraged short-sellers, predicting a sharp decline in the stock. The failure of the trial and Shkreli’s influence sent shares tumbling by more than 85%, from nearly $30 per share to under $5.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWhat It Means:\u003c/strong\u003e This setback emphasizes the significant risks in Alzheimer's drug development. With most Alzheimer’s trials failing, investors now question the credibility of Cassava’s lead drug. While the company still has resources to pivot, the stock’s credibility has been deeply shaken, and the road ahead is uncertain.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eStock Reaction:\u003c/strong\u003e Yesterday the stock opened at $30 but closed near $5, reflecting a swift and steep sell-off. The market’s reaction shows how quickly investor sentiment can turn negative on biotech stocks, particularly in high-risk, high-reward sectors like Alzheimer’s treatment.\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003e2. Poseida Therapeutics (NASDAQ: PSTX)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: Poseida is a biopharmaceutical company specializing in gene therapies, particularly CAR-T treatments for cancer.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe\u003c/strong\u003e \u003cstrong\u003eNews\u003c/strong\u003e: Poseida announced a significant partnership with Roche, securing $110 million upfront and up to $1 billion in potential milestones. This deal is aimed at accelerating Poseida's CAR-T therapies and other cell and gene therapy technologies.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWhat\u003c/strong\u003e \u003cstrong\u003eIt\u003c/strong\u003e \u003cstrong\u003eMeans\u003c/strong\u003e: This collaboration is a major validation for Poseida’s technology, especially in the competitive CAR-T space, which has attracted attention due to its potential to treat cancers. The cash infusion from Roche is expected to fuel further research and development.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eStock\u003c/strong\u003e \u003cstrong\u003eReaction\u003c/strong\u003e: Poseida opened at $9.26, up over 200%, rising slightly to close at $9.38. The market responded favorably to the news, viewing the Roche deal as a solid indication of Poseida’s future potential in the cancer treatment landscape.\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003e3. KULR Technology Group (NYSE: KULR)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: KULR specializes in thermal management technologies for energy storage and aerospace.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe\u003c/strong\u003e \u003cstrong\u003eNews\u003c/strong\u003e: KULR Technology Group has received a U.S. Navy contract to develop its Internal Short Circuit (ISC) technology to operate at higher temperatures. This upgrade is important for both military and commercial applications, especially in aviation where it aligns with safety standards. The ISC devices, originally developed with NASA and NREL, simulate controlled thermal runaway in lithium-ion cells for more accurate and safer testing of battery behavior in extreme conditions.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWhat\u003c/strong\u003e \u003cstrong\u003eIt\u003c/strong\u003e \u003cstrong\u003eMeans\u003c/strong\u003e: The Navy contract could serve as a major stepping stone for KULR, providing the company with exposure to one of the most demanding industries for thermal solutions. This deal not only enhances KULR’s credibility but may also open doors for similar partnerships in the aerospace and defense sectors.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eStock\u003c/strong\u003e \u003cstrong\u003eReaction\u003c/strong\u003e: The stock opened at $0.80 and climbed another 20% reaching $0.96 by mid-morning on volume that is 1,000%+ higher than average.\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003e4. POET Technologies (NASDAQ: POET)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: POET is a leader in photonics technology, designing advanced semiconductor solutions aimed at AI, telecommunications, and data storage.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe\u003c/strong\u003e \u003cstrong\u003eNews\u003c/strong\u003e: POET Technologies (NASDAQ: POET) is ramping up production of its optical engines to meet the increasing demand from AI applications. A recent report highlighted that while many companies in the UK are adopting AI, few have integrated it into their manufacturing processes, which could hinder innovation and productivity. The report suggests that government support and regulations could help accelerate AI adoption in industries.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWhat\u003c/strong\u003e \u003cstrong\u003eIt\u003c/strong\u003e \u003cstrong\u003eMeans\u003c/strong\u003e: As AI applications continue to expand, POET’s new platform could be a game-changer. The optical interposer aims to address the bottlenecks in data processing by enabling faster, more efficient communication between chips, which is crucial for AI and big data.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eStock\u003c/strong\u003e \u003cstrong\u003eReaction\u003c/strong\u003e: POET opened at $4.38 and rose to $5.35 (up 22%) by mid-day on volume 3x higher than average.\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003e5. SurgePays (NASDAQ: SURG)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: SurgePays provides financial services and prepaid wireless solutions for underserved markets.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe\u003c/strong\u003e \u003cstrong\u003eNews\u003c/strong\u003e:\u0026nbsp;SurgePays (SURG) has integrated its ClearLine marketing platform with PAX smart payment terminals, allowing merchants to deliver real-time promotions and offers during transactions. This integration leverages existing hardware to enhance customer engagement and streamline marketing efforts, helping retailers boost loyalty and sales. SurgePays aims to scale its retail presence by utilizing PAX's wide reach in the payment terminal industry.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWhat\u003c/strong\u003e \u003cstrong\u003eIt\u003c/strong\u003e \u003cstrong\u003eMeans\u003c/strong\u003e: SurgePays continues to capitalize on the significant need for affordable financial services and wireless solutions in underserved communities. This strong performance suggests the company’s business model is scaling effectively, positioning it well for future growth.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eStock\u003c/strong\u003e \u003cstrong\u003eReaction\u003c/strong\u003e: SurgePays opened at $2.00 and surged to $2.20, up 10%, trading average volume.\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003e6. TOYO Ventures Holdings (NASDAQ: TOYO)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: TOYO Co., Ltd. is a solar solutions company focused on becoming a full-service provider in the global market. It integrates all stages of the solar power supply chain, including wafer and silicon production, solar cell manufacturing, and photovoltaic module production. TOYO is positioned to produce high-quality solar cells at a competitive scale and cost.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe\u003c/strong\u003e \u003cstrong\u003eNews\u003c/strong\u003e: TOYO Co., Ltd (Nasdaq: TOYO) has secured a $150 million contract to supply high-efficiency solar cells to a major solar module manufacturer. The agreement will support solar module production in India and the U.S., leveraging TOYO’s advanced manufacturing capabilities in Vietnam and Ethiopia. This contract highlights the company's commitment to sustainable energy and the global shift towards renewable resources.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWhat\u003c/strong\u003e \u003cstrong\u003eIt\u003c/strong\u003e \u003cstrong\u003eMeans\u003c/strong\u003e: The $150 million contract is a major win for TOYO Co., Ltd, solidifying its role as a key player in the solar energy sector. It highlights the company’s advanced manufacturing capabilities and global reach, particularly in India and the U.S. For the market, the deal signals continued growth in the solar industry, boosting confidence in renewable energy technologies and potentially attracting more investment. TOYO’s expanded presence in key markets could strengthen its competitive position as demand for efficient solar cells rises..\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eStock\u003c/strong\u003e \u003cstrong\u003eReaction\u003c/strong\u003e: Shares opened at $5.56, up 39% to retrace to $4.50 by mid-morning and closing at $5.41 on eye-poping 1,500x average volume.\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003e7. Anavex Life Sciences (NASDAQ: AVXL)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e:\u0026nbsp;Anavex Life Sciences develops treatments for neurodegenerative disorders like Alzheimer's and Parkinson's. Its lead drug, ANAVEX®2-73, has shown positive results in Phase 2 trials, while the company is also developing ANAVEX®3-71 for Alzheimer's.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe\u003c/strong\u003e \u003cstrong\u003eNews\u003c/strong\u003e:Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug, blarcamesine (ANAVEX®2-73), to the European Medicines Agency (EMA) for the treatment of Alzheimer’s disease. Blarcamesine, an orally administered small molecule, showed significant clinical improvement in patients over 48 weeks, with better efficacy than approved therapies and a slower rate of neurodegeneration in early Alzheimer's patients. Its safety profile eliminates the need for routine MRI monitoring, making it a promising treatment option.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWhat\u003c/strong\u003e \u003cstrong\u003eIt\u003c/strong\u003e \u003cstrong\u003eMeans\u003c/strong\u003e:\u0026nbsp;The MAA submission for blarcamesine to the EMA is a positive development for Anavex Life Sciences, potentially boosting its stock if approved. If successful, blarcamesine could open new revenue streams and strengthen investor confidence. For the broader market, this signals progress in Alzheimer’s treatment, potentially drawing more investment into biotech, especially in neurodegenerative diseases.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eStock\u003c/strong\u003e \u003cstrong\u003eReaction\u003c/strong\u003e: Anavex opened at $10.30 up 10% from Monday's close, but cratered almost 20% from that high by mid-afternoon closing nearly flat from the previous day's close on slightly higher than average volume.\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003eBe The First to Know:\u0026nbsp;\u003ca target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https://wealthyvc.com/newsletter-sign-up/\"\u003eOur email list eats first! Get exclusive alerts on explosive stock picks like AST\u0026nbsp;SpaceMobile (NASDAQ: ASTS) which shot up\u0026nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003chr\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003ca target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https://x.com/WealthyVC\"\u003eFollow us on Twitter\u003c/a\u003e\u003cbr\u003e\u003ca target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https://www.instagram.com/wealthyventurecapital/\"\u003eFollow us on Instagram\u003c/a\u003e\u003cbr\u003e\u003ca target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https://www.facebook.com/TheWealthyVentureCapitalist/?locale=zh_CN\"\u003eFollow us on Facebook\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003ca target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https://www.facebook.com/groups/WealthyVC\"\u003eJoin the Discussion in the WVC Facebook Investor Group\u003c/a\u003e\u003c/p\u003e\u003cp\u003eHave a Stock Tip or New\u0026nbsp; Story Suggestion? Email us at Invest@WealthyVC.com\u003c/p\u003e\u003cp\u003eDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.\u003c/p\u003e\u003cp\u003eThis article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.\u003c/p\u003e","created_at":"2024-12-02T18:49:04Z","featured_image":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/wealthyvc_12445ce5f9.png","featured_image_attributes":{"alt_text":"","caption":"","url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/wealthyvc_12445ce5f9.png"},"headline":"News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market","image_url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/wealthyvc_12445ce5f9.png","meta_description":"","meta_keywords":"","meta_title":"","primary_symbol_code":"AVXL","sid":"cJ9kstRRhB","source":{"id":1075,"source_name":"Stocktwits Contributor","url_domain":"stocktwits.com"},"subcategory":{"id":3,"name":"Equity","parent_id":2},"summary":"","symbol_codes":["AVXL","KULR","MAXN","POET","PSTX","SAVA","SURG","TOYO"],"tags":[{"id":10,"tag_name":"Retail"}],"type":"article","updated_at":"2024-12-02T18:59:56Z","url_slug":"news-movers-your-daily-digest-of-stocks-that-released-news-which-moved-the-market"},{"author":{"description":"Prabhjote Gill is a senior writer at Stocktwits, the largest social network for investors and traders. She covers US markets and writes extensively on stocks, commodities, and other asset classes with a keen interest in cryptocurrencies, technology, energy, and sustainable investing.","designation":"Senior Writer","id":14,"name":"Prabhjote Gill","profile_avatar":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Prabhjote_DP_67623a9828.jpg","profile_link":"","social_media_links":{"facebook":"https://www.linkedin.com/in/prabhjotegill/","twitter":"https://x.com/pabsgill","website":"https://stocktwits.com/prabhgill"},"type":"Stocktwits"},"canonical_url":"","category":{"id":2,"name":"Markets"},"content":"\u003cp\u003eShares of Anavex Life Sciences Corp. (\u003ca class=\"mention\" data-mention=\"$AVXL\" data-symbol-id=\"AVXL\" href=\"https://stocktwits.com/symbol/AVXL\" target=\"_blank\"\u003e$AVXL\u003c/a\u003e) surged as much as 11% in pre-market trading Tuesday after the company filed for approval of its oral Alzheimer's drug with the European Medicines Agency (EMA).\u003c/p\u003e\u003cp\u003eThe biopharmaceutical company is looking for market authorization for blarcamesine, an oral treatment designed for Alzheimer’s Disease.\u0026nbsp;\u003c/p\u003e\u003cp\u003eThe drug has shown promising results in clinical trials with patients improving significantly over a 48-week period. The company cited ADAS-Cog13 scores improving by more than 2 points, which means the treatment may have helped slow cognitive decline.\u003c/p\u003e\u003cp\u003eThe company also said that its treatment is more clinically effective as compared to approved therapies while slowing neurodegeneration in early-stage Alzheimer’s patients,\u003c/p\u003e\u003cp\u003eAnavex claims blarcamesine’s advantages include its ease of use – taken just once a day, it does not require routine MRIs and a favorable safety profile.\u003c/p\u003e\u003cp\u003e\"Blarcamesine's safety and efficacy profile could represent a novel treatment that could be complementary or an alternative to anti-beta amyloid monoclonal antibody drugs,” said Juan Carlos Lopez-Talavera, the head of research and development at Anavex.\u0026nbsp;\u003c/p\u003e\u003cp\u003eD. Boral Capital has maintained a ‘Buy’ rating on Anavex with a $46 price target after Cassava Sciences' (\u003ca class=\"mention\" data-mention=\"$SAVA\" data-symbol-id=\"SAVA\" href=\"https://stocktwits.com/symbol/SAVA\" target=\"_blank\"\u003e$SAVA\u003c/a\u003e) Phase 3 trial for simufilam\u0026nbsp;\u003ca href=\"https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh\"\u003efailed\u003c/a\u003e in mild-to-moderate Alzheimer's disease.\u0026nbsp;\u003c/p\u003e\u003cp\u003eThe investment bank believes that Anavex’s treatment, which works by activating the sigma-1 receptor, could give it an edge over therapies like simlufilam that focus on narrower mechanisms.\u0026nbsp;\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003cimg style=\"aspect-ratio:1303/296;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_26_090241_50b7cdc087.png\" alt=\"Screenshot 2024-11-26 090241.png\" width=\"1303\" height=\"296\"\u003e\u003cfigcaption\u003eAnavex Life Sciences Corp. Sentiment and Message Volume on Nov 26 as of 9:00 a.m. ET | Source: Stocktwits\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003eRetail sentiment around Anavex jumped into the ‘extremely bullish’ (80/100)\u0026nbsp; territory in pre-market trading on Tuesday along with an uptick in chatter to ‘extremely high’ (77/100).\u003c/p\u003e\u003cp\u003eRetail investors on Stockwits were cheering the company’s first-ever EMA submission.\u003c/p\u003e\u003cp\u003e\u003cstembedurl\u003ehttps://stocktwits.com/5RingsPatsRule/message/594105457\u003c/stembedurl\u003e\u003c/p\u003e\u003cp\u003e\u003cstembedurl\u003ehttps://stocktwits.com/Factanonverba/message/594105443\u003c/stembedurl\u003e\u003c/p\u003e\u003cp\u003e\u003cstembedurl\u003ehttps://stocktwits.com/Minnesotastockdude/message/594069500\u003c/stembedurl\u003e\u003c/p\u003e\u003cp\u003eAnavex is expected to report its fourth-quarter earnings on Friday with Wall Street expecting a loss of $0.16 per share on no revenue.\u0026nbsp;\u003c/p\u003e\u003cp\u003eThe stock has gained 69% so far this year, outperforming the broader market.\u003c/p\u003e\u003cp\u003e\u003ci\u003eFor updates and corrections email newsroom[at]stocktwits[dot]com.\u003c/i\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eRead also:\u0026nbsp;\u003c/strong\u003e\u003ca href=\"https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh\"\u003e\u003cstrong\u003eCassava Sciences Stock Craters After Alzheimer’s Disease Trial Flops: Retail’s Devastated\u003c/strong\u003e\u003c/a\u003e\u003c/p\u003e","created_at":"2024-11-26T14:26:59Z","featured_image":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/alzheimer_1703005_1920_1_74a84685ea.jpg","featured_image_attributes":{"alt_text":"Anavex is expected to report its fourth-quarter earnings on Friday, Nov. 29. | Source: Pixabay","caption":"Anavex is expected to report its fourth-quarter earnings on Friday, Nov. 29. | Source: Pixabay","url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/alzheimer_1703005_1920_1_74a84685ea.jpg"},"headline":"Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon","image_url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/alzheimer_1703005_1920_1_74a84685ea.jpg","meta_description":"D. Boral Capital believes Anavex’s Alzheimer’s treatment is superior to Cassava Sciences' approach.","meta_keywords":"anavex stock, anavex stock price, alzheimers disease, blarcamesine, anavex life sciences corporation, cassava sciences stock, cassava sciences, cassava sciences stock price\n","meta_title":"Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon","primary_symbol_code":"AVXL","sid":"cJIWpqeRgx","source":{"id":1071,"source_name":"Stocktwits","url_domain":"stocktwits.com"},"subcategory":{"id":3,"name":"Equity","parent_id":2},"summary":"D. Boral Capital believes Anavex’s Alzheimer’s treatment is superior to Cassava Sciences' approach.\n","symbol_codes":["AVXL","SAVA","VTI","IWM"],"tags":[{"id":2,"tag_name":"Trending"},{"id":3,"tag_name":"Small Cap"},{"id":4,"tag_name":"Premarket"},{"id":10,"tag_name":"Retail"}],"type":"article","updated_at":"2024-11-26T14:26:59Z","url_slug":"anavex-stock-jumps-pre-market-on-oral-alzheimer-drug-european-approval"},{"author":{"description":"Shanthi is a Senior Writer at Stocktwits and she brings with her more than two decades of experience in financial journalism. She has a bachelor's degree in Agricultural Sciences and a post-graduate degree in management. At Stocktwits, she writes on stocks, ETFs and macroeconomics, given her interest in analyzing the intertwining variables that shape investor sentiment.","designation":"Senior Writer","id":15,"name":"Shanthi M","profile_avatar":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/shanthi_v2_compressed_98c13b83cf.png","profile_link":"","social_media_links":{"facebook":"https://www.linkedin.com/in/shanthi-rexaline-1390b18","twitter":"https://x.com/shanthirex?lang=en","website":"https://stocktwits.com/Shanthi_Rexaline"},"type":"Stocktwits"},"canonical_url":"","category":{"id":2,"name":"Markets"},"content":"\u003cp\u003eShares of Anavex Life Sciences Corp. ($AVXL) defied the broader market weakness and rallied on Thursday following a clinical trial readout.\u003c/p\u003e\u003cp\u003eNew York-based Anavex announced new data from the Phase 2b/3 study of its investigational drug candidate blarcamesin, administered as an once-daily oral formulation, demonstrating pre-specified clinical efficacy in people with early Alzheimer’s disease.\u0026nbsp;\u003c/p\u003e\u003cp\u003eThe drug candidate, codenamed ANAVEX 2-73 worked through upstream activation of SIGMAR1, which is an integral membrane protein.\u003c/p\u003e\u003cp\u003eAnalysis of Phase 2b/3 data showed that over 48 weeks, blarcamesine\u0026nbsp;significantly slowed clinical progression by 36.3% in the primary endpoint - Alzheimer’s Disease Assessment Scale-Cognitive 13-item, or ADAS-Cog13, scale, in the intention-to-treat\u0026nbsp;analysis, the neurology-focused small-cap biopharma said.\u0026nbsp;\u003c/p\u003e\u003cp\u003eJuan Carlos Lopez-Talavera, Head of R\u0026amp;D at Anavex, said, “The advantage of blarcamesine is that it is a small oral molecule that exerts clinical benefits on cognition and neurodegeneration and could be appealing because of its route of administration and good comparative safety profile.”\u003c/p\u003e\u003cp\u003eThe company said it is on track for regulatory submission of blarcamesine in Europe in the fourth quarter.\u003c/p\u003e\u003cp\u003eThe data was presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in Madrid, Spain.\u003c/p\u003e\u003cp\u003eRetail sentiment\u0026nbsp;on Stocktwits has brightened following the data release,\u0026nbsp;making\u0026nbsp;Anavex stock the sixth-most trending\u0026nbsp;ticker on Stocktwits.\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003ca href=\"https://stocktwits.com/symbol/AVXL\"\u003e\u003cimg style=\"aspect-ratio:627/142;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/avxl_sentiment_b45388096b.png\" alt=\"avxl-sentiment.png\" width=\"627\" height=\"142\"\u003e\u003c/a\u003e\u003cfigcaption\u003eAVXL sentiment and message volume October 31, 2024, as of 2:45 am ET | Source:\u0026nbsp;Stocktwits\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003eThe\u0026nbsp;sentiment meter trended in the “extremely bullish” (95/100)\u0026nbsp;territory, improving from a “neutral” position a day ago, with message volume spiking to “extremely high.”\u003c/p\u003e\u003cp\u003eOne Stocktwits user\u0026nbsp;sees scope for further upside in the near term. While noting that the short interest in the stock is 21%,\u0026nbsp;the user said a short squeeze-fueled rally could materialize if the European Medicines Agency accepts the regulatory application for\u0026nbsp;blarcamesine.\u003c/p\u003e\u003cp\u003e\u003cstembedurl\u003ehttps://stocktwits.com/badprecog/message/590798832\u003c/stembedurl\u003e\u003c/p\u003e\u003cp\u003eAs of 2:45 pm ET, Anavex shares rallied 16.29% to $6.64, having pulled back from an intraday high of $7.37. The stock has crossed the $7 threshold for the first time this year.\u003c/p\u003e\u003cp\u003eRead Next:\u0026nbsp;\u003ca href=\"https://stocktwits.com/news-articles/markets/equity/apple-to-report-q4-results-after-the-closing-bell-on-thursday/cJ2C2TSRBB\"\u003eApple Stock Slips Ahead Of Q4 Results As Analyst Loses Sleep Over Guidance: Retail Mood Stays Sour\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003ci\u003eFor updates and corrections email \u003c/i\u003e\u003ca target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"mailto:newsroom@stocktwits.com\"\u003e\u003ci\u003enewsroom@stocktwits.com\u003c/i\u003e\u003c/a\u003e\u003ci\u003e\u0026nbsp;\u003c/i\u003e\u003c/p\u003e","created_at":"2024-10-31T18:46:57Z","featured_image":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/pexels_shvetsa_4226219_alzheimer_s_5aa657bb30.jpg","featured_image_attributes":{"alt_text":"Anavex plans to file regulatory application for its Alzheimer's drug candidate in Europe.","caption":"Anavex plans to file regulatory application for its Alzheimer's drug candidate in Europe. | Photo Courtesy of Anna Shvets via Pexels","url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/pexels_shvetsa_4226219_alzheimer_s_5aa657bb30.jpg"},"headline":"Anavex Life Sciences Stock Spikes On Late-Stage Alzheimer’s Drug Trial Data, Retail Mood Upbeat","image_url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/pexels_shvetsa_4226219_alzheimer_s_5aa657bb30.jpg","meta_description":"Anavex' once-daily drug candidate demonstrated pre-specified clinical efficacy in people with early Alzheimer’s disease. ","meta_keywords":"avxl stock, avxl stock price, anavex stock price, anavex stock, biopharma stock, alzheimer's disease","meta_title":"Anavex Life Sciences Stock Spikes On Late-Stage Alzheimer’s Drug Trial Data, Retail Mood Upbeat","primary_symbol_code":"AVXL","sid":"cJ2C9MkRBi","source":{"id":1071,"source_name":"Stocktwits","url_domain":"stocktwits.com"},"subcategory":{"id":3,"name":"Equity","parent_id":2},"summary":"Anavex' once-daily drug candidate demonstrated pre-specified clinical efficacy in people with early Alzheimer’s disease. \n","symbol_codes":["AVXL","IWV"],"tags":[{"id":2,"tag_name":"Trending"},{"id":3,"tag_name":"Small Cap"},{"id":10,"tag_name":"Retail"},{"id":16,"tag_name":"Announcements"}],"type":"article","updated_at":"2024-10-31T18:46:57Z","url_slug":"anavex-life-sciences-stock-spikes-on-late-stage-alzheimer-s-drug-trial-data-retail-mood-upbeat"},{"author":{"description":"Ramakrishnan is a senior writer at Stocktwits, the largest social network for investors and traders. He specializes in covering the US markets and writes extensively on stocks, commodities, ETFs, and other asset classes, with a soft spot for EV companies and Big Tech.","designation":"Senior Staff Writer","id":3,"name":"Ramakrishnan M","profile_avatar":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ram_author_image_resized_and_compressed_1_0022abb723.jpg","profile_link":"","social_media_links":{"facebook":"https://in.linkedin.com/in/ramakrishnan-m","twitter":"https://x.com/heyram27?lang=en","website":"https://stocktwits.com/BangaloreBidder"},"type":"Stocktwits"},"canonical_url":"","category":{"id":2,"name":"Markets"},"content":"\u003cp\u003eRetail investors are honing in on three lesser-known stocks before the opening bell, according to Stocktwits data. Market participants are focused heavily on big-tech earnings and the Fed’s rate cut decision this week, but news for these three stocks is taking precedence in early trading.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eIovance Biotherapeutics Inc. (IOVA):\u003c/strong\u003e The biopharma company's stock price dipped over 10% to $8.30 pre-market after a Piper Sandler downgrade from Overweight to Neutral and a price target reduction from $19 to $10. Stocktwits sentiment mirrored the analyst's shift, flipping from bullish a day ago to bearish (33/100) as at 8.30 am ET. The downgrade stemmed from concerns about the slow adoption of IOVA's recently approved melanoma treatment, Amtagvi.\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003ca href=\"https://stocktwits.com/symbol/IOVA\"\u003e\u003cimg style=\"aspect-ratio:1322/310;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IOVA_sentiment_and_message_volume_score_premarket_Jul_29_1989b50a47.png\" alt=\"IOVA sentiment and message volume score premarket Jul 29.png\" width=\"1322\" height=\"310\"\u003e\u003c/a\u003e\u003cfigcaption\u003eIOVA sentiment and message volume score premarket 8.30 am ET Jul 29\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003eAnalyst conversations with treatment centers revealed only 10-15% of eligible patients received the infusion so far due to manufacturing limitations. Consequently, Piper Sandler’s Q2 revenue forecast for Amtagvi has been halved from an earlier consensus estimate of $24 million. The full-year revenue forecast has also been cut.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eAnavex Life Sciences Corporation (AVXL)\u003c/strong\u003e: Shares of the neuro-disease focused biopharma company surged nearly 14% to $7.68 pre-market, following data from the company showing that its oral Alzheimer's treatment, Blarcamesine, slowed clinical decline in early-stage patients. This development follows EF Hutton's initiation of coverage last week with a Buy rating and a $46 price target, representing a nearly 500% upside potential.\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003ca href=\"https://stocktwits.com/symbol/AVXL\"\u003e\u003cimg style=\"aspect-ratio:1324/316;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_sentiment_and_message_volume_score_premarket_Jul_29_11457e6cd0.png\" alt=\"AVXL sentiment and message volume score premarket Jul 29.png\" width=\"1324\" height=\"316\"\u003e\u003c/a\u003e\u003cfigcaption\u003eAVXL sentiment and message volume score premarket 8.30 am ET Jul 29.png\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003eAdditionally, the company's lead therapy, ANAVEX2-73, remains on track for regulatory submission by year-end. Retail investor sentiment on Stocktwits remained bullish (57/100) with high message volume, reflecting continued investor interest.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eAST SpaceMobile Inc. (ASTS)\u003c/strong\u003e: The space communications start-up's shares dipped slightly by 1.80% to $18.50 pre-market following last week’s 44% rise. ews of completing construction and testing of its first five Bluebird communications satellites, which are reportedly scheduled for shipment to Cape Canaveral next month for a September launch by SpaceX.\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003ca href=\"https://stocktwits.com/symbol/ASTS\"\u003e\u003cimg style=\"aspect-ratio:1326/304;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ASTS_sentiment_and_message_volume_score_premarket_Jul_29_f510308b88.png\" alt=\"ASTS sentiment and message volume score premarket Jul 29.png\" width=\"1326\" height=\"304\"\u003e\u003c/a\u003e\u003cfigcaption\u003eASTS sentiment and message volume score premarket 8.30 am ET Jul 29\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003eNotably, AST has secured investments from major technology and telecommunication giants like Verizon, Google (Alphabet), and a new U.S. government contract through a prime contractor. Retail investor sentiment on Stocktwits remained extremely bullish (83/100) with very high message volume, mirroring trends from the previous session. Popular posts on the platform focused on upcoming catalysts like CEO Abel Avellan's conference appearance later this week, potential FCC approval updates, and launch timeline developments.\u003c/p\u003e","created_at":"2024-07-29T13:13:34Z","featured_image":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Trending_stocks_a6dc630a4e.jpg","featured_image_attributes":{"url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Trending_stocks_a6dc630a4e.jpg"},"headline":"Pre-Market Movers: IOVA, AVXL, ASTS Catch Retail’s Eye","image_url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Trending_stocks_a6dc630a4e.jpg","meta_description":"Iovance Biotherapeutics fell sharply after a downgrade, dragging retail sentiment along. Anavex Life Sciences is finding favor on a positive drug trial update, while AST SpaceMobile is riding high on last week’s update.","meta_keywords":"Iovance Biotherapeutics, Anavex Life Sciences, AST SpaceMobile, trending stocks","meta_title":"Pre-Market Movers: IOVA, AVXL, ASTS Catch Retail’s Eye","primary_symbol_code":"IOVA","sid":"c7rjDyARbZ","source":{"id":1071,"source_name":"Stocktwits","url_domain":"stocktwits.com"},"subcategory":{"id":3,"name":"Equity","parent_id":2},"summary":"Iovance Biotherapeutics fell sharply after a downgrade, dragging retail sentiment along. Anavex Life Sciences is finding favor on a positive drug trial update, while AST SpaceMobile is riding high on last week’s update.","symbol_codes":["IOVA","AVXL","ASTS"],"tags":[{"id":2,"tag_name":"Trending"},{"id":4,"tag_name":"Premarket"},{"id":10,"tag_name":"Retail"}],"type":"article","updated_at":"2024-07-29T13:13:34Z","url_slug":"iova-avxl-asts-top-trending-retail-stocks-premarket"},{"author":{"description":"Ramakrishnan is a senior writer at Stocktwits, the largest social network for investors and traders. He specializes in covering the US markets and writes extensively on stocks, commodities, ETFs, and other asset classes, with a soft spot for EV companies and Big Tech.","designation":"Senior Staff Writer","id":3,"name":"Ramakrishnan M","profile_avatar":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ram_author_image_resized_and_compressed_1_0022abb723.jpg","profile_link":"","social_media_links":{"facebook":"https://in.linkedin.com/in/ramakrishnan-m","twitter":"https://x.com/heyram27?lang=en","website":"https://stocktwits.com/BangaloreBidder"},"type":"Stocktwits"},"canonical_url":"","category":{"id":2,"name":"Markets"},"content":"\u003cp\u003eU.S. stocks rose on Friday morning as investors digested the latest inflation data, which reinforced expectations of a September interest rate cut. The broader market exhibited a mixed performance in the previous session, with early optimism stemming from strong GDP data fading as tech giants dragged down the Nasdaq and S\u0026amp;P 500.\u003c/p\u003e\u003cp\u003eHere’s a look at the top three stocks that captured retail investors’ attention ahead of the opening bell today:\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWindtree Therapeutics Inc (WINT)\u003c/strong\u003e\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003ca href=\"https://stocktwits.com/symbol/WINT\"\u003e\u003cimg style=\"aspect-ratio:1316/320;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/WINT_sentiment_and_message_volume_score_on_Jul_26_58f5cea25d.png\" alt=\"WINT sentiment and message volume score on Jul 26.png\" width=\"1316\" height=\"320\"\u003e\u003c/a\u003e\u003cfigcaption\u003eWINT sentiment and message volume score premarket on Jul 26\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003eShares of Windtree Therapeutics surged by an impressive 150% in pre-market trading to reach a high $9.40. The biopharma company announced an update on its novel heart failure treatment, istaroxime, igniting a buying frenzy among retail investors.\u0026nbsp;\u003c/p\u003e\u003cp\u003eStocktwits data revealed overwhelmingly bullish sentiment (71/100), with message volume reaching its highest level this year (90/100). While the stock has experienced a significant decline of over 73% year-to-date, today's surge has injected a dose of optimism among investors.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eDexcom Inc (DXCM)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIn stark contrast to Windtree's performance, Dexcom Inc witnessed a dramatic decline of over 36% in pre-market trading, settling in the mid $60s. The medical device company's disappointing second-quarter revenue results and a weak FY24 revenue guidance for its glucose monitoring devices triggered a sell-off. Despite the price drop, several analysts maintained price targets well above current levels, suggesting potential upside in the long term.\u0026nbsp;\u003c/p\u003e\u003cp\u003eHowever, retail investor sentiment on Stocktwits plummeted to its lowest point this year (10/100), reflecting the bearish outlook, while message volumes reached a 2024 peak (96/100). Concerns about management’s inability to adequately communicate business issues and its plan to fix it, as well as market share impacts from the adoption of GLP-1 weight loss drugs is keeping retail away.\u003cbr\u003e\u0026nbsp;\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003ca href=\"https://stocktwits.com/symbol/DXCM\"\u003e\u003cimg style=\"aspect-ratio:1324/314;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DXCM_sentiment_and_message_volume_score_on_Jul_26_17d563e160.png\" alt=\"DXCM sentiment and message volume score on Jul 26.png\" width=\"1324\" height=\"314\"\u003e\u003c/a\u003e\u003cfigcaption\u003eDXCM sentiment and message volume score premarket on Jul 26\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003e\u003cstrong\u003eAnavex Life Sciences Corporation (AVXL)\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eShares of Anavex Life Sciences Corporation climbed over 4% in pre-market trading to a high of $7.22, with retail sentiment on Stocktwits at bullish levels (65/100).\u0026nbsp;\u003c/p\u003e\u003cp\u003eThe neuro-disease-focused biopharma company received a boost from EF Hutton analyst Jason Kolbert, who initiated coverage with a Buy rating and a price target of $46. The analyst highlighted the company's lead therapy, ANAVEX2-73, for Alzheimer's Disease (AD), which is on track for regulatory submission by the end of the year. The potential market for ANAVEX2-73, coupled with its broader therapeutic applications, has fueled investor optimism.\u003c/p\u003e\u003cfigure class=\"image\"\u003e\u003ca href=\"https://stocktwits.com/symbol/AVXL\"\u003e\u003cimg style=\"aspect-ratio:1320/312;\" src=\"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_sentiment_and_message_volume_score_on_Jul_26_d22a8e0bab.png\" alt=\"AVXL sentiment and message volume score on Jul 26.png\" width=\"1320\" height=\"312\"\u003e\u003c/a\u003e\u003cfigcaption\u003eAVXL sentiment and message volume score premarket on Jul 26\u003c/figcaption\u003e\u003c/figure\u003e\u003cp\u003e\u003ca href=\"https://www.vecteezy.com/photo/29286690-ai-generative-business-man-standing-in-the-stock-market-realistic-image-ultra-hd-high-design-very-detailed\"\u003e\u003ci\u003ePhoto\u003c/i\u003e\u003c/a\u003e\u003ci\u003e courtesy of syedqaseem on Vecteezy\u003c/i\u003e\u003c/p\u003e","created_at":"2024-07-26T14:13:30Z","featured_image":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Trending_stocks_monitor_98bbcbf4b7.jpg","featured_image_attributes":{"url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Trending_stocks_monitor_98bbcbf4b7.jpg"},"headline":"WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Before the Bell","image_url":"https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Trending_stocks_monitor_98bbcbf4b7.jpg","meta_description":"Two stocks are sparking optimism on Stocktwits with watchers passionately discussing potential catalysts, while one is losing a lot of favor following its disappointing earnings and outlook. ","meta_keywords":"Trending stocks, Windtree Therapeutics, Dexcom, Anavex Life Sciences, Premarket trends","meta_title":"WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Premarket","primary_symbol_code":"WINT","sid":"c7rfXPwRbi","source":{"id":1071,"source_name":"Stocktwits","url_domain":"stocktwits.com"},"subcategory":{"id":3,"name":"Equity","parent_id":2},"summary":"Two stocks are sparking optimism on Stocktwits with watchers passionately discussing potential catalysts, while one is losing a lot of favor following its disappointing earnings and outlook. ","symbol_codes":["WINT","DXCM","AVXL"],"tags":[{"id":2,"tag_name":"Trending"},{"id":4,"tag_name":"Premarket"},{"id":10,"tag_name":"Retail"}],"type":"article","updated_at":"2024-07-26T14:15:30Z","url_slug":"wint-dxcm-avxl-top-trending-retail-stocks-premarket"},{"author":{},"canonical_url":"https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-anavex-life-sciences-corporationavxl-urged-to-join-class-action--contact-levi--korsinsky-to-learn-more-302142771.html","category":{"id":0},"content":"","created_at":"2024-05-14T13:00:17Z","headline":"Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact Levi \u0026 Korsinsky to Learn More","image_url":"https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg?p=facebook","primary_symbol_code":"AVXL","sid":"c7jCs9mbjOIP","source":{"id":93,"source_name":"PR Newswire","url_domain":"PR Newswire"},"subcategory":{"id":0},"summary":"Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact Levi \u0026 Korsinsky to Learn More Shareholders that lost money on Anavex Life Sciences...","symbol_codes":["AVXL"],"tags":null,"type":"article","updated_at":"2024-05-14T13:00:17Z"}]},"tracking":{"instrumentClass":"Stock","instrumenttype":"Stock","pid":"symbol-avxl","quotetype":"Biotechnology","s1":"symbol","ticker":"AVXL"},"dehydratedState":{"mutations":[],"queries":[{"state":{"data":{"cursor":{"more":true,"pageNum":1,"limit":10},"symbols":[{"id":36510,"symbol":"FARTCOIN.X","symbolMic":"FARTCOIN.X","exchange":"CRYPTO","region":"X","title":"Fartcoin","aliases":[],"isFollowing":false,"watchlistCount":1048,"hasPricing":true,"instrumentClass":"CRYPTO","liveEvent":false,"sector":null,"industry":null,"logoUrl":"https://logos.stocktwits-cdn.com/FARTCOIN-X.png","trending":true,"trendingScore":10.9044,"trends":{"all":1,"region":1,"exchange":1,"summary":"Following recent online discussions, the cryptocurrency Fartcoin ($FARTCOIN.X) is trending due to its humorous name and volatile price action. While many view it skeptically as a potential scam or a symbol of crypto's speculative nature, others are actively buying and discussing its price movements, leading to significant price swings. This highlights the ongoing debate within the crypto community regarding meme coins and their role in the market.","summaryAt":"2025-04-06T14:00:50Z"},"features":{"alertsPrice":false,"socialData":true,"trendingMessages":false,"earnings":false},"cusip":null,"isin":null,"shouldSeoIndex":true,"rank":1,"priceData":{"PercentChange":0.0667111408,"Change":0.0003,"Last":0.45,"DateTime":"2025-04-06 14:47:43","Symbol":"FARTCOIN.X","symbol":"FARTCOIN.X","Identifier":"FARTCOIN.X","Type":"crypto","type":"crypto","LastClose":"0.45","LastCloseTime":"2025-04-06 14:47:43","High":null,"Low":null,"Open":null,"PreviousClose":null,"ExtendedHoursPrice":null,"ExtendedHoursChange":null,"ExtendedHoursPercentChange":null,"Volume":null,"LastSize":null}},{"id":18189,"symbol":"SAFEMOON.X","symbolMic":"SAFEMOON.X","exchange":"CRYPTO","region":"X","title":"SafeMoon","aliases":[],"isFollowing":false,"watchlistCount":41976,"hasPricing":true,"instrumentClass":"CRYPTO","liveEvent":false,"sector":null,"industry":null,"logoUrl":"https://logos.stocktwits-cdn.com/placeholder.png","trending":true,"trendingScore":7.30643,"trends":{"all":2,"region":2,"exchange":2,"summary":"Following the guilty plea of SafeMoon's CTO and amid recent price volatility, the community is actively debating the legitimacy of the VGX Foundation's involvement and the project's future. While some believe the foundation is revitalizing the token, others remain skeptical, highlighting past controversies and concerns about potential scams; broader market context is unclear but the project is trending among crypto enthusiasts.","summaryAt":"2025-04-06T14:10:59Z"},"features":{"alertsPrice":false,"socialData":true,"trendingMessages":false,"earnings":false},"cusip":null,"isin":null,"shouldSeoIndex":true,"rank":2,"priceData":{"PercentChange":0,"Change":0,"Last":0.0000018,"DateTime":"2023-09-26 01:44:10","Symbol":"SAFEMOON.X","symbol":"SAFEMOON.X","Identifier":"SAFEMOON.X","Type":"crypto","type":"crypto","LastClose":"1.8e-06","LastCloseTime":"2023-09-26 01:44:10","High":null,"Low":null,"Open":null,"PreviousClose":null,"ExtendedHoursPrice":null,"ExtendedHoursChange":null,"ExtendedHoursPercentChange":null,"Volume":null,"LastSize":null}},{"id":39083,"symbol":"GC.X","symbolMic":"GC.X","exchange":"CRYPTO","region":"X","title":"GCoin","aliases":[],"isFollowing":false,"watchlistCount":67,"hasPricing":true,"instrumentClass":"CRYPTO","liveEvent":false,"sector":null,"industry":null,"logoUrl":"https://logos.stocktwits-cdn.com/GC-X.png","trending":true,"trendingScore":7.1686,"trends":{"all":3,"region":3,"exchange":3,"summary":"Following the launch of Mint Round 3 for its NFT fractional ownership of real estate, GCoin ($GC.X) is trending due to excitement around its innovative real-world asset (RWA) model built on Hedera Hashgraph ($HBAR.X). The community is enthusiastic about the potential for revenue sharing and the long-term value proposition of crypto-backed real estate, while some anticipate significant growth potential. This activity is occurring within a broader market context of increasing interest in RWA within the crypto space.","summaryAt":"2025-04-06T14:00:49Z"},"features":{"alertsPrice":false,"socialData":true,"trendingMessages":false,"earnings":false},"cusip":null,"isin":null,"shouldSeoIndex":false,"rank":3,"priceData":{"PercentChange":24.04683,"Change":0.00120503,"Last":0.00621623,"DateTime":"2025-04-06 14:47:48","Symbol":"GC.X","Identifier":"GC.X","Type":"crypto","LastClose":"0.00621623","LastCloseTime":"2025-04-06 14:47:48","High":null,"Low":null,"Open":null,"PreviousClose":null,"ExtendedHoursPrice":null,"ExtendedHoursChange":null,"ExtendedHoursPercentChange":null,"Volume":null,"LastSize":null}},{"id":1387,"symbol":"COHU","symbolMic":"COHU.XNAS","exchange":"NASDAQ","region":"US","title":"Cohu, Inc.","aliases":[],"isFollowing":false,"watchlistCount":1225,"hasPricing":true,"instrumentClass":"Stock","liveEvent":false,"sector":"ElectronicTechnology","industry":"Semiconductors","logoUrl":"https://logos.stocktwits-cdn.com/placeholder.png","trending":true,"trendingScore":5.41128,"trends":{"all":4,"region":1,"exchange":1,"summary":"Following a Stifel analyst report upgrade and recent news of Cohu's expansion into the silicon carbide burn-in test market, investors are discussing the company's strategic acquisitions and long-term growth prospects in key markets like 5G and automotive. While some express optimism about Cohu's potential for share gains and positive estimate revisions, others highlight risks associated with pricing dynamics and the company's reliance on China.","summaryAt":"2025-04-06T14:16:13Z"},"tradeStatus":"FRACTIONAL","features":{"alertsPrice":true,"socialData":true,"trendingMessages":false,"earnings":true},"cusip":"192576106","isin":"US1925761066","shouldSeoIndex":true,"rank":4,"fundamentals":{"instrumentClass":"Stock","salesOrRevenue":"401.779","priceToBook":0.7745,"totalCash":"206.407","dividendsPerShareSecurity":"0","beta":1.5757,"earningsGrowth":"-351.1130","enterpriseOverEBITDA":"","floatCurrent":"44.9535","5YearAveragePERatio":"29.17","fiscalPeriodEndDate":"12/31/2024 12:00:00 AM","totalDebt":"32.407","50DayMovingAverage":19.0326,"numberOfEmployees":"3024","marketCapitalization":"624.9798","totalExpenses":"476.271","businessDescription":"Cohu, Inc. engages in the provision of back-end semiconductor equipment and services. It offers test and handling capital equipment, interface products, and related services to the semiconductor and electronics manufacturing industries. The company was founded in 1947 and is headquartered in Poway, CA.","grossIncomeMargin":35.0297053852989,"lastUpdated":"04/06/2025","sharesHeldByInstitutions":44.241281,"totalAssets":"999.415","revenuePerEmployee":"132863.426","industryName":"Semiconductors","name":"Cohu, Inc.","eBITDA":0,"revenueToAssets":"0.4020","sectorName":"Electronic Technology","pEGRatio":"-0.17","totalEnterpriseValue":"1009.62436","bookValuePerShare":"17.27568","averageDailyVolumeLast3Months":"510495.1452","dividendYieldSecurity":"0","symbol":"COHU","ePS":-1.4884,"dividendPayoutRatio":"","sharesOutstanding":"49.601","totalLiabilities":"142.524","dividendExDate":"","dividendRate":0,"highPriceLast52Weeks":36.6,"lowPriceLast52Weeks":12.57,"pERatio":-8.99,"averageDailyVolumeLastMonth":622658.4762,"marketCap":624.9798},"priceData":{"High":13.57,"Last":12.865,"LastSize":118258,"ExtendedHoursType":"PostMarket","ExtendedHoursChange":-0.515,"ISO8601":"2025-04-04T20:00:00Z","Type":"equity","DateTime":"2025-04-04 19:33:18","Identifier":"COHU","Open":13.12,"Low":12.57,"Volume":943664,"PreviousCloseDate":"2025-04-03","PercentChange":-6.327,"Outcome":"Success","UTCOffset":"-4","Symbol":"COHU","PreviousClose":13.72,"Change":-0.855,"ExtendedHoursPrice":12.865,"ExtendedHoursPercentChange":-3.849,"ExtendedHoursDateTime":"2025-04-04 19:33:18","Message":"Delay times are 15 mins for NASDAQ.","LastClose":"13.38","LastCloseTime":"2025-04-04 16:00:00"}},{"id":38020,"symbol":"ETF500.X","symbolMic":"ETF500.X","exchange":"CRYPTO","region":"X","title":"Elon Trump Fart","aliases":[],"isFollowing":false,"watchlistCount":1242,"hasPricing":true,"instrumentClass":"CRYPTO","liveEvent":false,"sector":null,"industry":null,"logoUrl":"https://logos.stocktwits-cdn.com/ETF500-X.png","trending":true,"trendingScore":5.25959,"trends":{"all":5,"region":4,"exchange":4,"summary":"Following recent allegations of fraud against its founder, \"Zack Morris,\" the cryptocurrency ETF500.X is trending as the community grapples with contrasting perspectives; some remain staunchly supportive, emphasizing the project's community and potential, while others express concerns and skepticism. This situation unfolds amid broader market volatility affecting the crypto sector.","summaryAt":"2025-04-06T14:05:53Z"},"features":{"alertsPrice":false,"socialData":true,"trendingMessages":false,"earnings":false},"cusip":null,"isin":null,"shouldSeoIndex":false,"rank":5,"priceData":{"Last":0.00456348,"DateTime":"2025-04-06 14:48:30","Symbol":"ETF500.X","Identifier":"ETF500.X","Type":"crypto","PercentChange":-15.22109,"Change":-0.000819321674060175,"LastClose":"0.00456348","LastCloseTime":"2025-04-06 14:48:30","High":null,"Low":null,"Open":null,"PreviousClose":null,"ExtendedHoursPrice":null,"ExtendedHoursChange":null,"ExtendedHoursPercentChange":null,"Volume":null,"LastSize":null}},{"id":26496,"symbol":"AERGO.X","symbolMic":"AERGO.X","exchange":"CRYPTO","region":"X","title":"AERGO","aliases":[],"isFollowing":false,"watchlistCount":336,"hasPricing":true,"instrumentClass":"CRYPTO","liveEvent":false,"sector":null,"industry":null,"logoUrl":"https://logos.stocktwits-cdn.com/AERGO-X.png","trending":true,"trendingScore":4.87718,"trends":{"all":6,"region":5,"exchange":5,"summary":"Following Binance's launch of AERGO futures trading, the cryptocurrency is trending, with the community buzzing about its potential price increase. While many express excitement, some warn of pump-and-dump schemes and volatility, creating contrasting perspectives. This event may also have broader implications for the crypto sector, especially for similar low-float cryptocurrencies.","summaryAt":"2025-04-06T14:40:54Z"},"features":{"alertsPrice":false,"socialData":true,"trendingMessages":false,"earnings":false},"cusip":null,"isin":null,"shouldSeoIndex":true,"rank":6,"priceData":{"PercentChange":31.1690250504,"Change":0.0163948914,"Last":0.0689948408,"DateTime":"2025-04-06 14:48:57","Symbol":"AERGO.X","symbol":"AERGO.X","Identifier":"AERGO.X","Type":"crypto","type":"crypto","LastClose":"0.0689948408","LastCloseTime":"2025-04-06 14:48:57","High":null,"Low":null,"Open":null,"PreviousClose":null,"ExtendedHoursPrice":null,"ExtendedHoursChange":null,"ExtendedHoursPercentChange":null,"Volume":null,"LastSize":null}},{"id":34699,"symbol":"BTC","symbolMic":"BTC.ARCX","exchange":"NYSEArca","region":"US","title":"Grayscale Bitcoin Mini Trust ETF","aliases":[],"isFollowing":false,"watchlistCount":2239,"hasPricing":true,"instrumentClass":"ExchangeTradedCommodity","liveEvent":false,"sector":"Unknown","industry":"Unknown","logoUrl":"https://logos.stocktwits-cdn.com/BTC.png","trending":true,"trendingScore":4.45397,"trends":{"all":8,"region":3,"exchange":1,"summary":"Following President Trump's announcement of a strategic Bitcoin reserve, the cryptocurrency is trending as the community discusses the implications for future adoption and price. While many are optimistic about this development, contrasting views highlight concerns about market manipulation and the potential for the announcement to be a pump and dump scheme. The broader market context involves ongoing economic uncertainty and concerns surrounding US trade relations, adding to the overall volatility.","summaryAt":"2025-04-06T13:55:59Z"},"features":{"alertsPrice":true,"socialData":true,"trendingMessages":false,"earnings":false},"cusip":"389930207","isin":"US3899302075","shouldSeoIndex":true,"rank":7,"fundamentals":{"name":"Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest","industryName":"","eBITDA":0,"instrumentClass":"ExchangeTradedCommodity","dividendsPerShareSecurity":"","earningsGrowth":"","beta":2.724,"enterpriseOverEBITDA":"","floatCurrent":"","5YearAveragePERatio":"","fiscalPeriodEndDate":"","totalDebt":"","50DayMovingAverage":40.1724,"numberOfEmployees":"","marketCapitalization":"","totalExpenses":"","businessDescription":"No company description","grossIncomeMargin":0,"lastUpdated":"04/06/2025","sharesHeldByInstitutions":0,"totalAssets":"","revenuePerEmployee":"","salesOrRevenue":"","totalCash":"","priceToBook":0,"revenueToAssets":"","pEGRatio":"","sectorName":"","totalEnterpriseValue":"","bookValuePerShare":"","dividendYieldSecurity":"","averageDailyVolumeLast3Months":"1182901.5806","symbol":"BTC","ePS":0,"dividendPayoutRatio":"","sharesOutstanding":"","totalLiabilities":"","dividendExDate":"","dividendRate":0,"highPriceLast52Weeks":48.07,"lowPriceLast52Weeks":22,"pERatio":0,"averageDailyVolumeLastMonth":915104.8571,"marketCap":0},"priceData":{"ExtendedHoursPrice":37.15,"ExtendedHoursChange":-0.06,"Identifier":"BTC","Open":36.58,"Last":37.15,"LastSize":259,"PreviousClose":36.31,"Outcome":"Success","Symbol":"BTC","Volume":1497070,"PercentChange":2.318,"Change":0.8400000000000001,"ExtendedHoursType":"PostMarket","ExtendedHoursPercentChange":-0.161,"UTCOffset":"-4","High":37.49,"PreviousCloseDate":"2025-04-03","Message":"Delay times are 15 mins for NYSEARCA.","ISO8601":"2025-04-04T20:00:00Z","Type":"equity","Low":36.22,"ExtendedHoursDateTime":"2025-04-04 19:58:18","DateTime":"2025-04-04 19:58:18","LastClose":"37.21","LastCloseTime":"2025-04-04 16:00:00"}},{"id":13439,"symbol":"NTRP","symbolMic":"NTRP.XNAS","exchange":"NASDAQ","region":"US","title":"NextTrip Inc.","aliases":[],"isFollowing":false,"watchlistCount":12173,"hasPricing":true,"instrumentClass":"Stock","liveEvent":false,"sector":"TechnologyServices","industry":"PackagedSoftware","logoUrl":"https://logos.stocktwits-cdn.com/placeholder.png","trending":true,"trendingScore":3.11625,"trends":null,"tradeStatus":"WHOLE","features":{"alertsPrice":true,"socialData":true,"trendingMessages":false,"earnings":true},"cusip":"826598609","isin":"US8265986096","shouldSeoIndex":true,"rank":8,"fundamentals":{"dividendsPerShareSecurity":"0","beta":0.5977,"earningsGrowth":"36.9268","enterpriseOverEBITDA":"","floatCurrent":"1.40603","5YearAveragePERatio":"","fiscalPeriodEndDate":"2/29/2024 12:00:00 AM","50DayMovingAverage":5.1184,"totalDebt":"0.828277","numberOfEmployees":"14","marketCapitalization":"10.5995","totalExpenses":"6.138109","grossIncomeMargin":-681.96781703404,"businessDescription":"NextTrip, Inc. engages in the provision of travel technology solutions. It connects people to new places and discoveries by utilizing digital media engagement, seasoned planning expertise, and unique inventory to curate custom vacations across the globe. The company was founded on December 23, 1985 and is headquartered in Santa Fe, NM.","lastUpdated":"04/06/2025","sharesHeldByInstitutions":0.000608,"revenuePerEmployee":"32768","totalAssets":"5.088842","industryName":"Packaged Software","name":"NextTrip Inc.","eBITDA":0,"priceToBook":-6.0489,"revenueToAssets":"0.1050","totalCash":"0.323805","instrumentClass":"Stock","salesOrRevenue":"0.458752","pEGRatio":"","sectorName":"Technology Services","totalEnterpriseValue":"1.18748526","bookValuePerShare":"2.9863","dividendYieldSecurity":"0","averageDailyVolumeLast3Months":"38473.4032","symbol":"NTRP","ePS":-32.1512,"dividendPayoutRatio":"","sharesOutstanding":"1.0473","totalLiabilities":"1.960813","dividendExDate":"","dividendRate":0,"highPriceLast52Weeks":8.5,"lowPriceLast52Weeks":1.385,"pERatio":-0.54,"averageDailyVolumeLastMonth":39757.3333,"marketCap":10.5995},"priceData":{"Outcome":"Success","Type":"equity","Identifier":"NTRP","Change":0.51,"ExtendedHoursType":"PostMarket","ISO8601":"2025-04-04T19:59:58Z","Open":5.19,"PreviousCloseDate":"2025-04-03","Volume":64709,"PercentChange":9.923,"ExtendedHoursChange":-0.16,"DateTime":"2025-04-04 19:49:11","UTCOffset":"-4","Symbol":"NTRP","High":6.06,"Low":5,"PreviousClose":5.32,"ExtendedHoursPrice":5.83,"ExtendedHoursPercentChange":-2.671,"ExtendedHoursDateTime":"2025-04-04 19:49:11","Message":"Delay times are 15 mins for NASDAQ.","Last":5.83,"LastSize":100,"LastClose":"5.99","LastCloseTime":"2025-04-04 15:59:58"}},{"id":15081,"symbol":"CPRI","symbolMic":"CPRI.XNYS","exchange":"NYSE","region":"US","title":"Capri Holdings Ltd","aliases":[],"isFollowing":false,"watchlistCount":3885,"hasPricing":true,"instrumentClass":"Stock","liveEvent":false,"sector":"RetailTrade","industry":"ApparelOrFootwearRetail","logoUrl":"https://logos.stocktwits-cdn.com/placeholder.png","trending":true,"trendingScore":4.69736,"trends":{"all":7,"region":2,"exchange":1,"summary":"Following the termination of its merger with Tapestry, Capri Holdings ($CPRI) is exploring the sale of its Versace and Jimmy Choo brands, leading to significant investor discussion regarding the company's future valuation and potential suitors. While the dominant community perspective anticipates increased share price due to asset sales, some express concern regarding the overall impact on the Michael Kors brand, driving uncertainty. The broader market context involves industry consolidation amid the luxury fashion sector, with potential implications for brand values and company restructuring.","summaryAt":"2025-04-06T14:20:56Z"},"tradeStatus":"FRACTIONAL","features":{"alertsPrice":true,"socialData":true,"trendingMessages":true,"earnings":true},"cusip":"G1890L107","isin":"VGG1890L1076","shouldSeoIndex":true,"rank":9,"fundamentals":{"priceToBook":1.603,"revenueToAssets":"0.7841","instrumentClass":"Stock","salesOrRevenue":"5170.00000000001","dividendsPerShareSecurity":"0","earningsGrowth":"-574.6479","beta":1.3206,"enterpriseOverEBITDA":"","floatCurrent":"114.979","5YearAveragePERatio":"9.76","fiscalPeriodEndDate":"3/31/2024 12:00:00 AM","totalDebt":"3575","50DayMovingAverage":21.5224,"marketCapitalization":"1712.0532","numberOfEmployees":"15100","totalExpenses":"4801.00000000001","grossIncomeMargin":60.9864603481626,"businessDescription":"Capri Holdings Ltd. operates as a global fashion luxury group. It engages in the design and distribution of sportswear, accessories, footwear and apparel of branded women's apparel, and accessories and men's apparel. The firm operates through the following segments: Versace, Jimmy Choo, and Michael Kors. The Versace segment sells Versace luxury ready-to-wear, accessories, footwear, and home furnishings through directly operated Versace boutiques. The Jimmy Choo segment sells Jimmy Choo luxury goods to end clients through directly operated Jimmy Choo stores. The Michael Kors segment sells Michael Kors products through four primary Michael Kors retail store formats such as Collection, Lifestyle, outlet stores, and e-commerce. The company was founded by Michael David Kors on December 13, 2002 and is headquartered in London, the United Kingdom.","lastUpdated":"04/06/2025","sharesHeldByInstitutions":102.673782,"totalAssets":"6689","revenuePerEmployee":"342384.106","industryName":"Apparel Or Footwear Retail","name":"Capri Holdings Ltd","eBITDA":0,"totalCash":"205","pEGRatio":"-0.05","sectorName":"Retail Trade","totalEnterpriseValue":"8671.753226","bookValuePerShare":"13.71007","averageDailyVolumeLast3Months":"3893775.6129","dividendYieldSecurity":"0","symbol":"CPRI","ePS":-1.957,"dividendPayoutRatio":"","sharesOutstanding":"116.629634","totalLiabilities":"5089","dividendExDate":"","dividendRate":0,"highPriceLast52Weeks":44.11,"lowPriceLast52Weeks":13.12,"pERatio":-1.7,"averageDailyVolumeLastMonth":3933072.9524,"marketCap":1712.0532},"priceData":{"LastSize":441210,"PercentChange":-2.928,"Open":14.51,"Volume":15230907,"Outcome":"Success","ExtendedHoursPrice":14.55,"ExtendedHoursDateTime":"2025-04-04 19:52:49","DateTime":"2025-04-04 19:52:49","Symbol":"CPRI","High":15.5,"Last":14.55,"PreviousCloseDate":"2025-04-03","Change":-0.43999999999999995,"ExtendedHoursPercentChange":0.207,"UTCOffset":"-4","Message":"Delay times are 15 mins for NYSE.","Type":"equity","Identifier":"CPRI","PreviousClose":14.99,"ExtendedHoursType":"PostMarket","ExtendedHoursChange":0.03,"ISO8601":"2025-04-04T20:00:00Z","Low":13.12,"LastClose":"14.52","LastCloseTime":"2025-04-04 16:00:00"}},{"id":12934,"symbol":"SILJ","symbolMic":"SILJ.ARCX","exchange":"NYSEArca","region":"US","title":"ETF Managers Group LLC - ETFMG Prime Junior Silver Miners ETF","aliases":[],"isFollowing":false,"watchlistCount":2588,"hasPricing":true,"instrumentClass":"ExchangeTradedFund","liveEvent":false,"sector":"Miscellaneous","industry":"InvestmentTrustsOrMutualFunds","logoUrl":"https://logos.stocktwits-cdn.com/placeholder.png","trending":true,"trendingScore":4.22688,"trends":{"all":9,"region":4,"exchange":2,"summary":"Following Trump's renewed tariff threats against China and other countries, the ETFMG Prime Junior Silver Miners ETF ($SILJ) is trending as investors debate the impact on precious metals. The dominant community perspective is bullish, anticipating market strength and increased demand for precious metals as a safe haven, while some express concern over potential economic disruptions. Broader implications include a potential sector rotation toward hard assets as geopolitical uncertainties persist.","summaryAt":"2025-04-06T13:51:08Z"},"tradeStatus":"FRACTIONAL","features":{"alertsPrice":true,"socialData":true,"trendingMessages":false,"earnings":false},"cusip":"032108649","isin":"US0321086490","shouldSeoIndex":true,"rank":10,"fundamentals":{"numberOfEmployees":"","dividendYieldSecurity":"","ePS":0,"floatCurrent":"","50DayMovingAverage":11.534,"averageDailyVolumeLast3Months":"3233588","5YearAveragePERatio":"","totalAssets":"","totalDebt":"","averageDailyVolumeLastMonth":3645622.381,"symbol":"SILJ","businessDescription":"No company description","totalExpenses":"","grossIncomeMargin":0,"marketCapitalization":"","instrumentClass":"ExchangeTradedFund","fiscalPeriodEndDate":"","dividendExDate":"","salesOrRevenue":"","pEGRatio":"","pERatio":0,"revenuePerEmployee":"","name":"Amplify ETF Trust - Amplify Junior Silver Miners ETF","revenueToAssets":"","dividendsPerShareSecurity":"","sharesOutstanding":"","lowPriceLast52Weeks":9.72,"sectorName":"Miscellaneous","bookValuePerShare":"","eBITDA":0,"highPriceLast52Weeks":15.18,"sharesHeldByInstitutions":0,"dividendRate":0.7206,"lastUpdated":"04/06/2025","industryName":"Investment Trusts Or Mutual Funds","totalLiabilities":"","priceToBook":0,"earningsGrowth":"","enterpriseOverEBITDA":"","totalCash":"","beta":0,"totalEnterpriseValue":"","dividendPayoutRatio":"","marketCap":0},"priceData":{"Low":10.35,"ExtendedHoursType":"PostMarket","Identifier":"SILJ","Open":11.2,"ExtendedHoursPercentChange":0,"DateTime":"2025-04-04 19:52:37","UTCOffset":"-4","Message":"Delay times are 15 mins for NYSEARCA.","Symbol":"SILJ","Type":"equity","Volume":6679503,"Outcome":"Success","PreviousCloseDate":"2025-04-03","PercentChange":-10.522,"Change":-1.23,"ExtendedHoursChange":0,"ExtendedHoursDateTime":"2025-04-04 19:52:37","High":11.3882,"Last":10.46,"ExtendedHoursPrice":10.46,"ISO8601":"2025-04-04T20:00:00Z","LastSize":3531,"PreviousClose":11.69,"LastClose":"10.46","LastCloseTime":"2025-04-04 16:00:00"}}],"indexes":[{"id":4979,"symbol":"DIA","symbolMic":"DIA.ARCX","exchange":"NYSEArca","region":"US","title":"SPDR Dow Jones Industrial Average ETF","aliases":[],"isFollowing":false,"watchlistCount":43035,"hasPricing":true,"instrumentClass":"ExchangeTradedFund","liveEvent":false,"price":null,"change":null,"percent":null,"priceData":{"Message":"Delay times are 15 mins for NYSEARCA.","Identifier":"DIA","LastSize":0,"PreviousClose":405.22,"Outcome":"Success","ExtendedHoursChange":0.33,"High":396.65,"Change":-21.67,"ExtendedHoursPrice":383.55,"Type":"equity","PreviousCloseDate":"2025-04-03","ExtendedHoursType":"PostMarket","DateTime":"2025-04-04 19:59:58","Symbol":"DIA","ExtendedHoursPercentChange":0.086,"ExtendedHoursDateTime":"2025-04-04 19:59:58","UTCOffset":"-4","Open":394.93,"Low":382.68,"Last":383.55,"Volume":8667239,"PercentChange":-5.343,"ISO8601":"2025-04-04T20:00:00Z","LastClose":"383.22","LastCloseTime":"2025-04-04 16:00:00"}},{"id":7271,"symbol":"SPY","symbolMic":"SPY.ARCX","exchange":"NYSEArca","region":"US","title":"SPDR S\u0026P 500 ETF","aliases":[],"isFollowing":false,"watchlistCount":569272,"hasPricing":true,"instrumentClass":"ExchangeTradedFund","liveEvent":false,"price":null,"change":null,"percent":null,"priceData":{"Open":523.67,"High":525.87,"PercentChange":-5.8100000000000005,"Change":-31.200000000000003,"ExtendedHoursPrice":505.5,"UTCOffset":"-4","Message":"Delay times are 15 mins for NYSEARCA.","ExtendedHoursType":"PostMarket","ExtendedHoursPercentChange":0.044,"ExtendedHoursDateTime":"2025-04-04 19:59:59","Symbol":"SPY","Identifier":"SPY","Low":505.06,"Volume":217965131,"PreviousClose":536.7,"ExtendedHoursChange":0.22,"ISO8601":"2025-04-04T20:00:00Z","Type":"equity","Last":505.5,"LastSize":0,"PreviousCloseDate":"2025-04-03","Outcome":"Success","DateTime":"2025-04-04 19:59:59","LastClose":"505.28","LastCloseTime":"2025-04-04 16:00:00"}},{"id":9581,"symbol":"QQQ","symbolMic":"NASDAQ","exchange":"NASDAQ","region":"US","title":"Invesco QQQ Trust Series 1","aliases":[{"0":"Q","1":"Q","2":"Q","3":"Q"}],"isFollowing":false,"watchlistCount":216314,"hasPricing":true,"instrumentClass":"ExchangeTradedFund","liveEvent":false,"price":null,"change":null,"percent":null,"priceData":{"ExtendedHoursPrice":422.18,"ExtendedHoursPercentChange":-0.116,"ExtendedHoursDateTime":"2025-04-04 19:59:59","Message":"Delay times are 15 mins for NASDAQ.","Type":"equity","ExtendedHoursType":"PostMarket","PercentChange":-6.327,"ISO8601":"2025-04-04T20:00:00Z","Last":422.18,"Low":422.67,"Volume":117088441,"ExtendedHoursChange":-0.49,"High":440.37,"Open":438.14,"LastSize":2180732,"PreviousClose":450.66,"PreviousCloseDate":"2025-04-03","Change":-28.479999999999997,"Outcome":"Success","DateTime":"2025-04-04 19:59:59","Identifier":"QQQ","Symbol":"QQQ","UTCOffset":"-4","LastClose":"422.67","LastCloseTime":"2025-04-04 16:00:00"}}],"regions":[{"0":"C","1":"A"},{"0":"U","1":"S"},{"0":"X"}],"debug":{"regions":[{"0":"C","1":"A"},{"0":"U","1":"S"},{"0":"X"}],"pageNum":0,"limit":10,"includePrices":true,"includeIndices":true,"indicesRegions":[]},"response":{"status":200}},"dataUpdateCount":1,"dataUpdatedAt":1743951231014,"error":null,"errorUpdateCount":0,"errorUpdatedAt":0,"fetchFailureCount":0,"fetchMeta":null,"isFetching":false,"isInvalidated":false,"isPaused":false,"status":"success"},"queryKey":["useFetchTrendingEnhancedQueryKey",{"class":"all","limit":10,"payloads":"indices,prices"}],"queryHash":"[\"useFetchTrendingEnhancedQueryKey\",{\"class\":\"all\",\"limit\":10,\"payloads\":\"indices,prices\"}]"}]},"deviceContext":{"desktop":true,"desktopDown":false,"mobile":false,"screen":false,"tablet":false,"tabletUp":true,"family":"other"},"everythingData":{"announcement":[],"events_present":false,"video_events_present":false},"flags":{"COM-194":false,"COM-327":false,"COM-393":false,"COM-519":false,"COM-532":false,"COM-62":{"US":[{"DIA":"DOW"},{"SPY":"S\u0026P 500"},{"QQQ":"NASDAQ"},{"IWM":"iShares Russell 2000 Index ETF"},{"ARKK":"ARK Innovation"}]},"COM-63":false,"COMMUNITY-110":true,"COMMUNITY-48":true,"COMSOC-14":true,"COMSOC-274":true,"COMSOC-275":true,"COMSOC-284":false,"COMSOC-285":false,"COMSOC-459":true,"COMSOC-465":true,"COMSOC-473":true,"COMSOC-5":false,"COMSOC-522":true,"COMSOC-600":true,"CORE-2473":false,"CORE1-1020":true,"CORE1-1151":true,"CORE1-1194":true,"CORE1-1253":true,"CORE1-1254":true,"CORE1-1350":false,"CORE1-1411":{"google":"https://stocktwits.onelink.me/NjIT/l3d56r44","apple":"https://stocktwits.onelink.me/NjIT/ttq0iuad"},"CORE1-1412":true,"CORE1-1697":false,"CORE1-1724":true,"CORE1-1827":true,"CORE1-1832":true,"CORE1-1966":true,"CORE1-2233":true,"CORE1-2295":true,"CORE1-2392-display-edge-annual-plan":true,"CORE1-2392-display-edge-monthly-plan":true,"CORE1-2392-use-new-marketing-page":true,"CORE1-2456":false,"CORE1-2490":true,"CORE1-2503":false,"CORE1-2527":false,"CORE1-2632-subscriptions-plan-term_default":true,"CORE1-2676-show-edge-annual-earlyadopter-plan":false,"CORE1-2779":false,"CORE1-2790":true,"CORE1-2956":true,"CORE1-3050":true,"CORE1-3071":true,"CORE1-3159":false,"CORE1-3174":false,"CORE1-3187":true,"CORE1-3282":false,"CORE1-3327":true,"CORE1-3338":false,"CORE1-3348":false,"CORE1-3354":true,"CORE1-3359":true,"CORE1-3399":true,"CORE1-3453":true,"CORE1-3464":true,"CORE1-3477":true,"CORE1-3745":true,"CORE1-3746":true,"CORE1-3775":false,"CORE1-3775-test-panel":false,"CORE1-3803":true,"CORE1-3807":true,"CORE1-3860":false,"CORE1-3862-desktop":200,"CORE1-3862-mobile":200,"CORE1-3933":true,"CORE1-397":false,"CORE1-3980":true,"CORE1-4035":false,"CORE1-4235":true,"CORE1-4365":true,"CORE1-4368":false,"CORE1-4419":true,"CORE1-4601":true,"CORE1-4972":true,"CORE1-5045":false,"CORE1-5051":true,"CORE1-5095":true,"CORE1-5122":false,"CORE1-5340":true,"CORE1-5345":true,"CORE1-5368":true,"CORE1-5392":true,"CORE1-5455":true,"CORE1-5464":true,"CORE1-5538":true,"CORE1-5583":true,"CORE1-5625":false,"CORE1-5674":true,"CORE1-5686-home-page":false,"CORE1-5686-symbol-page":false,"CORE1-5690":true,"CORE1-5723":true,"CORE1-5815":false,"CORE1-5827":false,"CORE1-5842":{},"CORE1-5884":false,"CORE1-641":false,"CORE1-671":true,"CORE1-795":false,"CORE1-864":false,"CORE1-873":true,"CORE1-873-modal":false,"DATATOOLS-137":true,"EVERY-100":true,"EVERY-110":false,"EVERY-126":false,"EVERY-144":true,"EVERY-150":true,"EVERY-178":"press-releases","EVERY-186":false,"EVERY-206":false,"EVERY-206-B":false,"EVERY-211":true,"EVERY-211-use-community-sentiment-flag-ssr":true,"EVERY-217":false,"EVERY-230":true,"EVERY-244-is-mounted-symbol-page-sidebar":false,"EVERY-250":true,"EVERY-254":90,"EVERY-254-initial-articles":true,"EVERY-274":true,"EVERY-291":false,"EVERY-3":true,"EVERY-337":false,"EVERY-353":true,"EVERY-358-articles":false,"EVERY-369":{},"EVERY-4":true,"EVERY-407":true,"EVERY-411":false,"EVERY-79":"press-releases","EVERY-91":false,"GROWTH-1010":true,"GROWTH-1085":false,"GROWTH-1107":true,"GROWTH-1152":false,"GROWTH-1195":false,"GROWTH-1206":true,"GROWTH-1212":"Popular","GROWTH-1252":"Sentiment","GROWTH-1302":false,"GROWTH-1357":true,"GROWTH-1386":true,"GROWTH-1459":"suggested","GROWTH-1470":true,"GROWTH-1489":true,"GROWTH-1517":true,"GROWTH-1554":false,"GROWTH-1568":true,"GROWTH-1570":true,"GROWTH-1601":true,"GROWTH-1623":true,"GROWTH-1643":"trending","GROWTH-1651":true,"GROWTH-1652":true,"GROWTH-1701":true,"GROWTH-1717":true,"GROWTH-1749":true,"GROWTH-1750":false,"GROWTH-1751":false,"GROWTH-1751-right-rail":false,"GROWTH-1797":"A","GROWTH-1852":false,"GROWTH-1893":true,"GROWTH-1984":false,"GROWTH-2069":true,"GROWTH-2074":true,"GROWTH-2097":true,"GROWTH-2138":true,"GROWTH-2173":true,"GROWTH-2197":true,"GROWTH-2220-side-bar-mid-left-ad-home-page":true,"GROWTH-2220-side-bar-mid-left-ad-symbol-page":false,"GROWTH-2220-side-bar-top-left-ad-home-page":true,"GROWTH-2220-side-bar-top-left-ad-symbol-page":false,"GROWTH-2245":true,"GROWTH-2246":true,"GROWTH-2273":true,"GROWTH-2304-Pre-tick-Newsletter-email-sign-up":true,"GROWTH-2304-Pre-tick-newsletter-google-apple-sign-up":true,"GROWTH-2309":true,"GROWTH-2369":true,"GROWTH-2394":false,"GROWTH-2394-scrolling-mobile-navbar":true,"GROWTH-2399":true,"GROWTH-2403-delaying-ad-query-params":false,"GROWTH-2403-hiding-left-rail-units-when-no-ad-fills":true,"GROWTH-2416":false,"GROWTH-2537":true,"GROWTH-2538":true,"GROWTH-2568":false,"GROWTH-2585-show-replies-in-following-stream":false,"GROWTH-2592":true,"GROWTH-2626-IN-unauthed-watchlist":{"name":"statis IN Watchlist","static":true,"symbols":[{"title":"Nifty 50","id":13409,"symbol":"NIFTY50.NSE"},{"symbol":"NIFTYBANK.NSE","title":"Nifty Bank","id":20004},{"symbol":"RELIANCE.NSE","title":"Reliance Industries Ltd.","id":19618},{"id":19706,"symbol":"ZOMATO.NSE","title":"Zomato Ltd."},{"symbol":"TCS.NSE","title":"Tata Consultancy Services","id":19623},{"symbol":"TATAMOTORS.NSE","title":"Tata Motors Ltd.","id":19466},{"id":19599,"symbol":"HDFCBANK.NSE","title":"HDFC Bank Ltd."},{"title":"ITC Ltd.","id":19608,"symbol":"ITC.NSE"},{"title":"Bitcoin","id":11418,"symbol":"BTC.X"},{"title":"Adani Enterprises Ltd","id":19792,"symbol":"ADANIENT.NSE"},{"symbol":"AXISBANK.NSE","title":"Axis Bank Ltd","id":19584},{"title":"Bajaj Finance Ltd","id":19586,"symbol":"BAJFINANCE.NSE"}],"id":4673581},"GROWTH-2626-US-unauthed-watchlist":{"name":"statis US Watchlist","static":true,"symbols":[{"id":7271,"symbol":"SPY","title":"SPDR S\u0026P 500 ETF"},{"symbol":"QQQ","title":"Invesco QQQ Trust Series 1","id":9581},{"title":"Bitcoin","id":11418,"symbol":"BTC.X"},{"id":686,"symbol":"AAPL","title":"Apple Inc."},{"title":"Tesla Inc","id":8660,"symbol":"TSLA"},{"id":2735,"symbol":"MSFT","title":"Microsoft Corporation"},{"id":2925,"symbol":"NVDA","title":"NVIDIA Corp"}],"id":4673580},"GROWTH-2687":"1","GROWTH-2691":false,"GROWTH-2698":false,"GROWTH-2704":true,"GROWTH-2705":true,"GROWTH-2710":true,"GROWTH-2712":true,"GROWTH-2739":false,"GROWTH-2744":1,"GROWTH-2753":false,"GROWTH-2761":true,"GROWTH-2784":true,"GROWTH-2801":true,"GROWTH-2809":0,"GROWTH-2814":false,"GROWTH-2840":true,"GROWTH-2882":true,"GROWTH-2904":true,"GROWTH-2917":true,"GROWTH-2951":true,"GROWTH-2970":true,"GROWTH-2992":true,"GROWTH-3030":2,"GROWTH-3051":true,"GROWTH-3056":true,"GROWTH-3086":true,"GROWTH-3150":true,"GROWTH-3184":true,"GROWTH-3197":true,"GROWTH-3264":false,"GROWTH-3349":true,"GROWTH-3413":true,"GROWTH-3536":true,"GROWTH-3536-cta":true,"GROWTH-3623":true,"GROWTH-3629":true,"GROWTH-3650":true,"GROWTH-3660":false,"GROWTH-788-animation":false,"GROWTH-788-toast":false,"GROWTH-795":true,"GROWTH-832":true,"GROWTH-881":false,"GROWTH-882":true,"GROWTH-891":true,"GROWTH-899":true,"GROWTH-904":true,"GROWTH-905":true,"GROWTH-914":true,"GROWTH-920":"market://details?id=org.stocktwits.android.activity\u0026referrer={code}","GROWTH-921":"https://apps.apple.com/app/id389157776","GROWTH-941":false,"GROWTH-942":false,"GROWTH-984":"Want to stay ahead of the game in the stock market? Join the Stocktwits community and connect with traders from around the world. Sign up with my referral link today!","GROWTH-985":"{ \"body\": \" Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below \\n \\n\", \"subject\": \" has invited you to join Stocktwits\" }","GROWTH-986":"Want to stay ahead of the game in the stock market? Join the Stocktwits community and connect with traders from around the world. Sign up with my referral link today!","POR-114":false,"POR-467":false,"POR-92":false,"PORT-76":false,"TRADING-2595":true,"TRADING-2664":false,"TRADING-2744":true,"TRADING-2988":true,"TRADING-3061":false,"TRADING-3663":false,"TRADING-4125":false,"TRADING-4133":false,"TRADING-4145":true,"TRADING-4146":true,"TRADING-4363":false,"TRADING-4520":false,"TRADING-4583":false,"TRADING-4592":false,"TRADING-4596":false,"TRADING-4621":false,"TRADING-4626":false,"TRADING-4689":false,"TRADING-4700":false,"WEB-1018":false,"WEB-1020":true,"WEB-1022":true,"WEB-1031":true,"WEB-1040":true,"WEB-1045":true,"WEB-1057":false,"WEB-1073":true,"WEB-1090":false,"WEB-1091":true,"WEB-1092":false,"WEB-1141":false,"WEB-1159":false,"WEB-1167":true,"WEB-1176":false,"WEB-1191":false,"WEB-1244":true,"WEB-1247":true,"WEB-1302":false,"WEB-1304":true,"WEB-1348":false,"WEB-1416":true,"WEB-1429":true,"WEB-1431":true,"WEB-1441":true,"WEB-1446":600,"WEB-1447":true,"WEB-1450":false,"WEB-1474":true,"WEB-1476":2000,"WEB-1487":true,"WEB-1514":true,"WEB-1524":false,"WEB-1525":false,"WEB-1543":false,"WEB-1564":false,"WEB-1573":true,"WEB-1583":false,"WEB-1584":false,"WEB-1596":false,"WEB-1597":true,"WEB-1604":false,"WEB-1612":false,"WEB-1633":false,"WEB-1639":true,"WEB-1640":false,"WEB-1649":true,"WEB-1650":false,"WEB-1651":true,"WEB-1657":true,"WEB-1659":false,"WEB-1666":true,"WEB-1668":false,"WEB-1671":true,"WEB-1674":true,"WEB-1678":true,"WEB-1679":false,"WEB-1680":true,"WEB-1682":true,"WEB-1695":true,"WEB-17":false,"WEB-1700":true,"WEB-1702":true,"WEB-1715":true,"WEB-1717":true,"WEB-1718":false,"WEB-1722":true,"WEB-1723":true,"WEB-1725":false,"WEB-1726":true,"WEB-1730":false,"WEB-1756":false,"WEB-1759":true,"WEB-1763":false,"WEB-1782":30,"WEB-1783":true,"WEB-1784":true,"WEB-1786":true,"WEB-1789":true,"WEB-1823":true,"WEB-1838":false,"WEB-1853":false,"WEB-1855":false,"WEB-1891":true,"WEB-1895":true,"WEB-1896":false,"WEB-1898":true,"WEB-1899":true,"WEB-1900":true,"WEB-1902":false,"WEB-1904":true,"WEB-1909":true,"WEB-1910":true,"WEB-1911":true,"WEB-1913":true,"WEB-1915":true,"WEB-1916":false,"WEB-1918":true,"WEB-1919":true,"WEB-1923":true,"WEB-1925":true,"WEB-1944":true,"WEB-1948":true,"WEB-1958":false,"WEB-1965":true,"WEB-2013":false,"WEB-2014":true,"WEB-2016":false,"WEB-2025":true,"WEB-2027":true,"WEB-2031":true,"WEB-2075":false,"WEB-2113":true,"WEB-2114":false,"WEB-2143":false,"WEB-2147":true,"WEB-2164":true,"WEB-2170":true,"WEB-2173":true,"WEB-2176":true,"WEB-2177":true,"WEB-2181":true,"WEB-2185":true,"WEB-2189":false,"WEB-2211":true,"WEB-2212":true,"WEB-2215":true,"WEB-2226":false,"WEB-2236":false,"WEB-2242":true,"WEB-2243":false,"WEB-2245":true,"WEB-2301":true,"WEB-2307":true,"WEB-347":false,"WEB-565":true,"WEB-654":["crazyegg"],"WEB-692":true,"WEB-742":false,"WEB-757":true,"WEB-759":true,"WEB-803":true,"WEB-806":false,"WEB-885":true,"WEB-886":true,"WEB-890":false,"WEB-912":true,"WEB-930":false,"WEB-980":false,"WEB-989":true,"WEB-990":true,"WEB-991":false,"WEB-992":3500,"WEB-994":true,"WEB-IO-DMS":false,"core-1-609-display-non-price-indicators-in-price-alerts":false,"core-1-663":false,"core-1-809":false,"core-1-889":true,"core-1-940-ios-trending-enabled":false,"core-1-947":false,"web-1368-autofocus-on-mobile-web-post-box":false,"web-1690-hide-show-indices-data-box-on-mobile-tablet-carousel":false,"web-1728-add-loader-icon-in-mobile-watchlist":false,"web-1907-grey-sparklines-on-rankings":true,"web-1950-remove-preload-image-on-conversation-page":true,"web-2035-web-version-in-footer":false,"web-2060-unblock-user-from-messages":true,"web-2091-reshared-message-notifications-do-not-fit-in-mobile-web":false,"web-2106-search-menu-does-not-scroll-on-mobile-web":false},"invalidateKeys":[["useFetchTrendingEnhancedQueryKey",{"class":"all","limit":10,"payloads":"indices,prices"}]],"regionSSR":"ALL","serverAsPath":"/symbol/AVXL","serverPathname":"/symbol/[symbol]/[[...tab]]","userData":{"cfCountry":"SG","isAuthenticated":false}},"deviceContext":{"desktop":true,"desktopDown":false,"mobile":false,"screen":false,"tablet":false,"tabletUp":true,"family":"other"},"flags":{"COM-194":false,"COM-327":false,"COM-393":false,"COM-519":false,"COM-532":false,"COM-62":{"US":[{"DIA":"DOW"},{"SPY":"S\u0026P 500"},{"QQQ":"NASDAQ"},{"IWM":"iShares Russell 2000 Index ETF"},{"ARKK":"ARK Innovation"}]},"COM-63":false,"COMMUNITY-110":true,"COMMUNITY-48":true,"COMSOC-14":true,"COMSOC-274":true,"COMSOC-275":true,"COMSOC-284":false,"COMSOC-285":false,"COMSOC-459":true,"COMSOC-465":true,"COMSOC-473":true,"COMSOC-5":false,"COMSOC-522":true,"COMSOC-600":true,"CORE-2473":false,"CORE1-1020":true,"CORE1-1151":true,"CORE1-1194":true,"CORE1-1253":true,"CORE1-1254":true,"CORE1-1350":false,"CORE1-1411":{"google":"https://stocktwits.onelink.me/NjIT/l3d56r44","apple":"https://stocktwits.onelink.me/NjIT/ttq0iuad"},"CORE1-1412":true,"CORE1-1697":false,"CORE1-1724":true,"CORE1-1827":true,"CORE1-1832":true,"CORE1-1966":true,"CORE1-2233":true,"CORE1-2295":true,"CORE1-2392-display-edge-annual-plan":true,"CORE1-2392-display-edge-monthly-plan":true,"CORE1-2392-use-new-marketing-page":true,"CORE1-2456":false,"CORE1-2490":true,"CORE1-2503":false,"CORE1-2527":false,"CORE1-2632-subscriptions-plan-term_default":true,"CORE1-2676-show-edge-annual-earlyadopter-plan":false,"CORE1-2779":false,"CORE1-2790":true,"CORE1-2956":true,"CORE1-3050":true,"CORE1-3071":true,"CORE1-3159":false,"CORE1-3174":false,"CORE1-3187":true,"CORE1-3282":false,"CORE1-3327":true,"CORE1-3338":false,"CORE1-3348":false,"CORE1-3354":true,"CORE1-3359":true,"CORE1-3399":true,"CORE1-3453":true,"CORE1-3464":true,"CORE1-3477":true,"CORE1-3745":true,"CORE1-3746":true,"CORE1-3775":false,"CORE1-3775-test-panel":false,"CORE1-3803":true,"CORE1-3807":true,"CORE1-3860":false,"CORE1-3862-desktop":200,"CORE1-3862-mobile":200,"CORE1-3933":true,"CORE1-397":false,"CORE1-3980":true,"CORE1-4035":false,"CORE1-4235":true,"CORE1-4365":true,"CORE1-4368":false,"CORE1-4419":true,"CORE1-4601":true,"CORE1-4972":true,"CORE1-5045":false,"CORE1-5051":true,"CORE1-5095":true,"CORE1-5122":false,"CORE1-5340":true,"CORE1-5345":true,"CORE1-5368":true,"CORE1-5392":true,"CORE1-5455":true,"CORE1-5464":true,"CORE1-5538":true,"CORE1-5583":true,"CORE1-5625":false,"CORE1-5674":true,"CORE1-5686-home-page":false,"CORE1-5686-symbol-page":false,"CORE1-5690":true,"CORE1-5723":true,"CORE1-5815":false,"CORE1-5827":false,"CORE1-5842":{},"CORE1-5884":false,"CORE1-641":false,"CORE1-671":true,"CORE1-795":false,"CORE1-864":false,"CORE1-873":true,"CORE1-873-modal":false,"DATATOOLS-137":true,"EVERY-100":true,"EVERY-110":false,"EVERY-126":false,"EVERY-144":true,"EVERY-150":true,"EVERY-178":"press-releases","EVERY-186":false,"EVERY-206":false,"EVERY-206-B":false,"EVERY-211":true,"EVERY-211-use-community-sentiment-flag-ssr":true,"EVERY-217":false,"EVERY-230":true,"EVERY-244-is-mounted-symbol-page-sidebar":false,"EVERY-250":true,"EVERY-254":90,"EVERY-254-initial-articles":true,"EVERY-274":true,"EVERY-291":false,"EVERY-3":true,"EVERY-337":false,"EVERY-353":true,"EVERY-358-articles":false,"EVERY-369":{},"EVERY-4":true,"EVERY-407":true,"EVERY-411":false,"EVERY-79":"press-releases","EVERY-91":false,"GROWTH-1010":true,"GROWTH-1085":false,"GROWTH-1107":true,"GROWTH-1152":false,"GROWTH-1195":false,"GROWTH-1206":true,"GROWTH-1212":"Popular","GROWTH-1252":"Sentiment","GROWTH-1302":false,"GROWTH-1357":true,"GROWTH-1386":true,"GROWTH-1459":"suggested","GROWTH-1470":true,"GROWTH-1489":true,"GROWTH-1517":true,"GROWTH-1554":false,"GROWTH-1568":true,"GROWTH-1570":true,"GROWTH-1601":true,"GROWTH-1623":true,"GROWTH-1643":"trending","GROWTH-1651":true,"GROWTH-1652":true,"GROWTH-1701":true,"GROWTH-1717":true,"GROWTH-1749":true,"GROWTH-1750":false,"GROWTH-1751":false,"GROWTH-1751-right-rail":false,"GROWTH-1797":"A","GROWTH-1852":false,"GROWTH-1893":true,"GROWTH-1984":false,"GROWTH-2069":true,"GROWTH-2074":true,"GROWTH-2097":true,"GROWTH-2138":true,"GROWTH-2173":true,"GROWTH-2197":true,"GROWTH-2220-side-bar-mid-left-ad-home-page":true,"GROWTH-2220-side-bar-mid-left-ad-symbol-page":false,"GROWTH-2220-side-bar-top-left-ad-home-page":true,"GROWTH-2220-side-bar-top-left-ad-symbol-page":false,"GROWTH-2245":true,"GROWTH-2246":true,"GROWTH-2273":true,"GROWTH-2304-Pre-tick-Newsletter-email-sign-up":true,"GROWTH-2304-Pre-tick-newsletter-google-apple-sign-up":true,"GROWTH-2309":true,"GROWTH-2369":true,"GROWTH-2394":false,"GROWTH-2394-scrolling-mobile-navbar":true,"GROWTH-2399":true,"GROWTH-2403-delaying-ad-query-params":false,"GROWTH-2403-hiding-left-rail-units-when-no-ad-fills":true,"GROWTH-2416":false,"GROWTH-2537":true,"GROWTH-2538":true,"GROWTH-2568":false,"GROWTH-2585-show-replies-in-following-stream":false,"GROWTH-2592":true,"GROWTH-2626-IN-unauthed-watchlist":{"name":"statis IN Watchlist","static":true,"symbols":[{"title":"Nifty 50","id":13409,"symbol":"NIFTY50.NSE"},{"symbol":"NIFTYBANK.NSE","title":"Nifty Bank","id":20004},{"symbol":"RELIANCE.NSE","title":"Reliance Industries Ltd.","id":19618},{"id":19706,"symbol":"ZOMATO.NSE","title":"Zomato Ltd."},{"symbol":"TCS.NSE","title":"Tata Consultancy Services","id":19623},{"symbol":"TATAMOTORS.NSE","title":"Tata Motors Ltd.","id":19466},{"id":19599,"symbol":"HDFCBANK.NSE","title":"HDFC Bank Ltd."},{"title":"ITC Ltd.","id":19608,"symbol":"ITC.NSE"},{"title":"Bitcoin","id":11418,"symbol":"BTC.X"},{"title":"Adani Enterprises Ltd","id":19792,"symbol":"ADANIENT.NSE"},{"symbol":"AXISBANK.NSE","title":"Axis Bank Ltd","id":19584},{"title":"Bajaj Finance Ltd","id":19586,"symbol":"BAJFINANCE.NSE"}],"id":4673581},"GROWTH-2626-US-unauthed-watchlist":{"name":"statis US Watchlist","static":true,"symbols":[{"id":7271,"symbol":"SPY","title":"SPDR S\u0026P 500 ETF"},{"symbol":"QQQ","title":"Invesco QQQ Trust Series 1","id":9581},{"title":"Bitcoin","id":11418,"symbol":"BTC.X"},{"id":686,"symbol":"AAPL","title":"Apple Inc."},{"title":"Tesla Inc","id":8660,"symbol":"TSLA"},{"id":2735,"symbol":"MSFT","title":"Microsoft Corporation"},{"id":2925,"symbol":"NVDA","title":"NVIDIA Corp"}],"id":4673580},"GROWTH-2687":"1","GROWTH-2691":false,"GROWTH-2698":false,"GROWTH-2704":true,"GROWTH-2705":true,"GROWTH-2710":true,"GROWTH-2712":true,"GROWTH-2739":false,"GROWTH-2744":1,"GROWTH-2753":false,"GROWTH-2761":true,"GROWTH-2784":true,"GROWTH-2801":true,"GROWTH-2809":0,"GROWTH-2814":false,"GROWTH-2840":true,"GROWTH-2882":true,"GROWTH-2904":true,"GROWTH-2917":true,"GROWTH-2951":true,"GROWTH-2970":true,"GROWTH-2992":true,"GROWTH-3030":2,"GROWTH-3051":true,"GROWTH-3056":true,"GROWTH-3086":true,"GROWTH-3150":true,"GROWTH-3184":true,"GROWTH-3197":true,"GROWTH-3264":false,"GROWTH-3349":true,"GROWTH-3413":true,"GROWTH-3536":true,"GROWTH-3536-cta":true,"GROWTH-3623":true,"GROWTH-3629":true,"GROWTH-3650":true,"GROWTH-3660":false,"GROWTH-788-animation":false,"GROWTH-788-toast":false,"GROWTH-795":true,"GROWTH-832":true,"GROWTH-881":false,"GROWTH-882":true,"GROWTH-891":true,"GROWTH-899":true,"GROWTH-904":true,"GROWTH-905":true,"GROWTH-914":true,"GROWTH-920":"market://details?id=org.stocktwits.android.activity\u0026referrer={code}","GROWTH-921":"https://apps.apple.com/app/id389157776","GROWTH-941":false,"GROWTH-942":false,"GROWTH-984":"Want to stay ahead of the game in the stock market? Join the Stocktwits community and connect with traders from around the world. Sign up with my referral link today!","GROWTH-985":"{ \"body\": \" Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below \\n \\n\", \"subject\": \" has invited you to join Stocktwits\" }","GROWTH-986":"Want to stay ahead of the game in the stock market? Join the Stocktwits community and connect with traders from around the world. Sign up with my referral link today!","POR-114":false,"POR-467":false,"POR-92":false,"PORT-76":false,"TRADING-2595":true,"TRADING-2664":false,"TRADING-2744":true,"TRADING-2988":true,"TRADING-3061":false,"TRADING-3663":false,"TRADING-4125":false,"TRADING-4133":false,"TRADING-4145":true,"TRADING-4146":true,"TRADING-4363":false,"TRADING-4520":false,"TRADING-4583":false,"TRADING-4592":false,"TRADING-4596":false,"TRADING-4621":false,"TRADING-4626":false,"TRADING-4689":false,"TRADING-4700":false,"WEB-1018":false,"WEB-1020":true,"WEB-1022":true,"WEB-1031":true,"WEB-1040":true,"WEB-1045":true,"WEB-1057":false,"WEB-1073":true,"WEB-1090":false,"WEB-1091":true,"WEB-1092":false,"WEB-1141":false,"WEB-1159":false,"WEB-1167":true,"WEB-1176":false,"WEB-1191":false,"WEB-1244":true,"WEB-1247":true,"WEB-1302":false,"WEB-1304":true,"WEB-1348":false,"WEB-1416":true,"WEB-1429":true,"WEB-1431":true,"WEB-1441":true,"WEB-1446":600,"WEB-1447":true,"WEB-1450":false,"WEB-1474":true,"WEB-1476":2000,"WEB-1487":true,"WEB-1514":true,"WEB-1524":false,"WEB-1525":false,"WEB-1543":false,"WEB-1564":false,"WEB-1573":true,"WEB-1583":false,"WEB-1584":false,"WEB-1596":false,"WEB-1597":true,"WEB-1604":false,"WEB-1612":false,"WEB-1633":false,"WEB-1639":true,"WEB-1640":false,"WEB-1649":true,"WEB-1650":false,"WEB-1651":true,"WEB-1657":true,"WEB-1659":false,"WEB-1666":true,"WEB-1668":false,"WEB-1671":true,"WEB-1674":true,"WEB-1678":true,"WEB-1679":false,"WEB-1680":true,"WEB-1682":true,"WEB-1695":true,"WEB-17":false,"WEB-1700":true,"WEB-1702":true,"WEB-1715":true,"WEB-1717":true,"WEB-1718":false,"WEB-1722":true,"WEB-1723":true,"WEB-1725":false,"WEB-1726":true,"WEB-1730":false,"WEB-1756":false,"WEB-1759":true,"WEB-1763":false,"WEB-1782":30,"WEB-1783":true,"WEB-1784":true,"WEB-1786":true,"WEB-1789":true,"WEB-1823":true,"WEB-1838":false,"WEB-1853":false,"WEB-1855":false,"WEB-1891":true,"WEB-1895":true,"WEB-1896":false,"WEB-1898":true,"WEB-1899":true,"WEB-1900":true,"WEB-1902":false,"WEB-1904":true,"WEB-1909":true,"WEB-1910":true,"WEB-1911":true,"WEB-1913":true,"WEB-1915":true,"WEB-1916":false,"WEB-1918":true,"WEB-1919":true,"WEB-1923":true,"WEB-1925":true,"WEB-1944":true,"WEB-1948":true,"WEB-1958":false,"WEB-1965":true,"WEB-2013":false,"WEB-2014":true,"WEB-2016":false,"WEB-2025":true,"WEB-2027":true,"WEB-2031":true,"WEB-2075":false,"WEB-2113":true,"WEB-2114":false,"WEB-2143":false,"WEB-2147":true,"WEB-2164":true,"WEB-2170":true,"WEB-2173":true,"WEB-2176":true,"WEB-2177":true,"WEB-2181":true,"WEB-2185":true,"WEB-2189":false,"WEB-2211":true,"WEB-2212":true,"WEB-2215":true,"WEB-2226":false,"WEB-2236":false,"WEB-2242":true,"WEB-2243":false,"WEB-2245":true,"WEB-2301":true,"WEB-2307":true,"WEB-347":false,"WEB-565":true,"WEB-654":["crazyegg"],"WEB-692":true,"WEB-742":false,"WEB-757":true,"WEB-759":true,"WEB-803":true,"WEB-806":false,"WEB-885":true,"WEB-886":true,"WEB-890":false,"WEB-912":true,"WEB-930":false,"WEB-980":false,"WEB-989":true,"WEB-990":true,"WEB-991":false,"WEB-992":3500,"WEB-994":true,"WEB-IO-DMS":false,"core-1-609-display-non-price-indicators-in-price-alerts":false,"core-1-663":false,"core-1-809":false,"core-1-889":true,"core-1-940-ios-trending-enabled":false,"core-1-947":false,"web-1368-autofocus-on-mobile-web-post-box":false,"web-1690-hide-show-indices-data-box-on-mobile-tablet-carousel":false,"web-1728-add-loader-icon-in-mobile-watchlist":false,"web-1907-grey-sparklines-on-rankings":true,"web-1950-remove-preload-image-on-conversation-page":true,"web-2035-web-version-in-footer":false,"web-2060-unblock-user-from-messages":true,"web-2091-reshared-message-notifications-do-not-fit-in-mobile-web":false,"web-2106-search-menu-does-not-scroll-on-mobile-web":false},"isSymbolPage":true,"symbolTab":"feed","userData":{"cfCountry":"SG","isAuthenticated":false}},"page":"/symbol/[symbol]/[[...tab]]","query":{"symbol":"AVXL"},"buildId":"Sywudl5heFtPLFfFDPbOW","assetPrefix":"https://chunks-prd.stocktwits-cdn.com","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[51499,21643],"gssp":true,"appGip":true,"scriptLoader":[]}</script></body></html>

Pages： 1 2 3 4 5 6 7 8 9 10